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INTRODUCTION 
 
Biomarker Concept 
A biomarker is defined as a quality objectively measured and evaluated 
as indicator of physiological and pathological processes or 
pharmacologic responses to a therapy (Biomarkers Definitions Working 
Group, 2001). In the past, biomarkers were primarily physiological 
indicators, for example body temperature rise is a biomarker for fever or 
blood pressure is used to determine the risk of stroke. More recently, 
biomarker is becoming a synonym for molecular marker, namely 
chemical molecules, genes, proteins and enzymes that can be measured 
in body fluids and are related to a specific pathology (i.e. transaminases 
levels as markers for liver functions). Also, biomarkers can be specific 
cells or complex organ functions and characteristic changes in biological 
structures. 
We can distinguish between two strictly-related kinds of biomarkers: 
disease-related and drug-related biomarkers. Disease-related biomarkers 
give an indication for a threat of disease (risk indicator or predictive 
biomarkers i.e. Anti-citrullinated protein/peptide antibody as marker for 
Rheumatoid Arthritis), if a disease already exists (diagnostic biomarkers 
i.e. prostate specific antigens for prostate cancer), or how a disease may 
develop in a patient (prognostic biomarker i.e. cancer biomarkers). In 
contrast, drug-related biomarkers indicate whether a drug will be 
effective in a specific patient and therefore, they should vary with a drug 
treatment. 
A number of diseases, such as Alzheimer’s disease, rheumatoid arthritis 
or Multiple Sclerosis, often begin with an early, symptom-free phase. In 
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these cases, biomarkers may help identifying high-risk individuals to 
develop a disease, so they can be treated before onset of the disease or 
either as soon as possible thereafter.  
In order to use a biomarker for diagnostic purposes, it should have some 
well-defined characteristics: 
 the sample material to use for the biomarker detection must be as 
easy to obtain as possible, with a low invasiveness. For example, 
this may be a blood sample, a urine or saliva sample, or even a 
drop of blood; 
 the assay for a biomarker should be as quick as possible. In fact, 
for rapid initiation of treatment, the speed with which a result is 
obtained from the biomarker test is critical. A test which delivers 
results only in few minutes is optimal. 
 the detection method for a biomarker must be accurate and as 
easy to carry out as possible. The results from different 
laboratories may not differ significantly from each other, and the 
biomarker must have proven its effectiveness for the diagnosis, 
prognosis and risk assessment of the disease in independent 
studies.  
Together with molecular biomarker assayed in biological fluids there are 
also other kinds of biomarkers referred as imaging biomarkers, 
developed using imaging technologies like coronary angiography, 
computed tomography, magnetic resonance imaging, positron emission 
tomography. 
Imaging biomarkers have many advantages: usually they are non-
invasive and produce intuitive, multidimensional results. Yielding both 
qualitative and quantitative data, they are usually relatively comfortable 
for patients and combined with other sources of information, they can be 
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very useful to help clinicians in a diagnosis. In contrast to these 
advantages, often the required analyses are expensive and may require 
the use of radiations or contrast liquids which can lead to allergies. For 
these reasons, molecular biomarkers are essential to develop large scale 
screenings on patient populations and can give, together with imaging 
biomarkers, more complete information. 
In the present study, I aimed to evaluate the possible role of active Matrix 
Metalloproteinase-9 (MMP-9) and Matrix Metalloproteinase-2 (MMP-2) 
as biomakers in inflammatory pathologies, since their involvement in 
inflammation is well documented but is still unclear (Opdenakker G et 
al., 2003; Cunningham et al., 2005; Yong VW, 2005; Fainardi et al., 
2006). Moreover, I also investigated the role of Neurofilament light and 
heavy subunits and N-Acetyl aspartic Acid as biomarkers of axonal 
damage in a neurodegenerative disorder like Primary Progressive 
Multiple Sclerosis (PPMS), as a lack of reliable data remains on the role 
of these markers in such MS subtype (Norgren N et al., 2003; Jasperse B 
et al., 2007; Teunissen CE et al., 2009). 
Gelatinases in inflammatory conditions 
Matrix Metalloproteases (MMPs) were discovered in 1962, and since 
then more than twenty five members of this family have been identified, 
cloned and sequenced (Lijnen HR. et al., 2001). 
The MMPs are endopeptidases zinc and calcium dependent which are 
classified on the basis of the recognized substrates and sequence 
homology in: collagenases, gelatinases, stromelysins, membrane-type 
metalloproteases (MT-MMPs) and matrilysins. 
Collectively, they are capable of degrading essentially all the 
Extracellular Matrix (ECM) components, playing an important role in 
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ECM remodeling during both physiological and pathological conditions. 
In fact they are expressed during embryonal development, tissue 
regeneration and wound repair (Van den Steen PE et al., 2002). Also, 
they play a role in pathological conditions such as rheumatoid arthritis, 
autoimmune disorders of the skin, chronic ulcerations, malignant tumors 
and metastasis (Van den Steen PE et al., 2002). 
One of the most complex MMPs family is the gelatinases family, that 
includes MMP-9 (Gelatinase B) and MMP-2 (Gelatinase A). Among 
these, MMP-9 has been associated with a large number of pathological 
conditions, such as acute respiratory distress syndrome, destructive lung 
disease, Sjögren’s syndrome, peripheral nerve injury, Guillain-Barré 
syndrome, blood-brain-barrier damage, Multiple Sclerosis, Alzheimer’s 
diseases, cancers and brain ischemia (Lacraz S et al., 1995). On the 
contrary, MMP-2 has been associated to both tissue repair and 
destruction in inflammatory pathologies (Yong VW, 2005). 
The objective of my study was to analyse in detail the role of gelatinases 
in pathological inflammatory conditions such as Multiple Sclerosis or 
Spontaneous Intra Cerebral Haemorrhage (SICH). Moreover, to better 
understand the real involvement of MMP-9 in inflammatory processes, I 
tried to assess in vitro the release of MMP-9 from neutrophils during 
environmental pH changes because an acidic pH in tissues is related to 
inflammatory conditions. 
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Catalytic	Domain	
The catalytic domain consist in 190 amino acids in MMP-9 and 205 
amino acids in MMP-2, and contains an highly conserved domain called 
Zinc Binding Domain, which coordinates a zinc ion through three 
histidines and is essential for the enzymatic activity 
(…AH401EXGH405XXGXXH411… in MMP-9 and 
…AH403EXGH407XXGXXH413… in MMP-2) (Van den Steen PE. et al., 
2002). Within the catalytic domain there are also one other zinc, 
coordinated by three histidines (His175, la His190 and His203 in MMP-9; 
His178, His180 and His193 in MMP-2), and two calcium ions; all these ions 
are essential to maintain the correct spatial structure for the interaction of 
the substrates with the active site (Massova I. et al., 1998). The 
secondary structure of the catalytic domain (Figure 3) consists in five β-
sheets that wrap around three α-helices. One important amino acid close 
to the catalytic zinc is the Glu402 in MMP-9 and Glu402 in MMP-2, which 
binds water molecules and is essential for the hydrolysis of the 
substrates. In addition, there are also two N-glycosylation sites in the 
Asn120 and Asn127 residues only in the catalytic domain of MMP-9. 
 Figure 3.
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this sequence there is another region of 54 amino acids called collagen 
V-like domain. It is rich in Ser/Thr/Pro and is heavily O-glycosylated: as 
the O-glycosylation confers to this region a rigid structure, probably the 
role of this sequence is to maintain the correct distance between the 
hemopexin-like domain and the other domains. 
Substrate specificity 
The specificity depends on primary sequence of the substrate: the 
endoproteases prefer the sequences that bind to the pocket of the catalytic 
site. However, also the three dimensional conformation of the substrate 
and the accessibility of the cleavage sequence are important features. 
Finally, the presence of exosites in the catalytic domain which can bind 
distant residues on the substrate can have a key role promoting the 
hydrolysis. 
Probably, the fibronectin II-like domain of gelatinases plays a role as 
exosite that binds collagens increasing the hydrolysis efficiency. 
The substrate specificity for MMP-9 and MMP-2 has been analyzed 
using synthetic short peptides as substrates, resembling the sequence 
Gly-Pro-Gln-Gly-Ile-Ala-Gly-Gln which correspond to the P4-P3-P2-P1-
P1’-P2’-P3’-P4’ sites in the substrate. Mutagenesis studies showed that 
MMP-9 has a preference for small amino acids (Gly, Ala, Pro) in the P1 
site, and hydrophobic residues (Ile, Leu, Tyr, Met) in the P1’ and P2 
sites. On the contrary, MMP-2 cleaves the substrate between the Glycine 
in the P1 site and a hydrophobic amino acid in the P1’ site, although in 
this last site hydroxylated and acid residues are tolerated (Van den Steen 
PE et al., 2002). 
Up to now, only a small number of physiologic substrates belonging to 
the extracellular matrix and cleaved by MMP-9 were described; the most 
12 
 
known are denatured collagens or gelatins. Moreover, also the type II and 
type V collagens can be cleaved by this enzyme. Other substrates that 
belong to the ECM include aggrecans, the link protein and elastin (Van 
den Steen PE et al., 2002) (Table 1). 
MMP-2 has a similar substrate specificity as MMP-9 for ECM 
compounds, although differences were observed in substrate type, 
catalytic efficiency and cleavage pattern of the same substrate for both 
gelatinases (i.e. gelatin). Among the ECM substrates, there are collagens 
I, IV, V, VII, X, XI, XIV, gelatin, elastin, fibronectin, laminin-1, 
laminin-5, galectin-3, aggrecans, decorin, proteoglycan link protein and 
osteonectin (Van den Steen PE et al., 2002). 
There are also several non-matrix proteins degraded by MMP-9 and 
MMP-2. MMP-9 is able to degrade myelin basic protein (which 
degradation can lead to the release of encephalitogenic peptides), α1-
antitrypsin and α1-antichimotrypsin, P substance, IL-2 receptor- α, TGF-
β, β-amiloyd peptide (Aβ1-40), IL-1β, proTNF- α. Recently, has been 
observed that MMP-9 can cleave six N-terminal amino acids from IL-8 
(1-77), generating another IL-8 form (7-77) which is more bioactive. 
Moreover, it can generate a positive feedback signal as IL-8 can 
stimulate the release of MMP-9 from neutrophils (Van den Steen PE et 
al., 2002). The non-ECM substrates degraded by MMP-2 include IL-1β, 
α1-PI, prolysyl oxidase fusion protein, MMP-1, MMP-9, MMP-13. 
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Table 1. ECM and non-ECM substrates for MMP-9and MMP-2. 
(Chakraborti S. et al., 2003) 
Protease ECM Substrates Non-ECM substrates 
MMP-9 
 
 
Collagens (IV, V, VII, 
X, XIV), gelatin, 
elastin, galectin-3, 
aggrecans, fibronectin, 
proteoglican link 
protein, entactin, 
osteonectin. 
 
Plasminogen, IL-1β, 
MBP, ET-1 (endotelin-1), 
amyloid peptide Aβ1-40, 
IL-8, GRO- α (growth-
related oncogene-α), SDF-
1 (stromal-cell derived 
factor-1), α1-antitrypsin, 
α1-antichimotrypsin, P 
substance, IL-2 receptor- 
α, TGF-β, proTNF- α. 
MMP-2 
 
Collagens (I, IV, V, VII, 
X, XI, XIV), gelatin, 
elastin, fibronectin, 
laminin-1, laminin-5, 
galectin-3, aggrecans, 
decorin, proteoglican 
link protein, 
osteonectin. 
 
IL-1β, α1-PI, prolysyl 
oxidase fusion protein, 
MMP-1, MMP-9, MMP-
13. 
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Regulation of Gelatinases 
The regulation of gelatinases occurs on different levels: 
 Transcription; 
 Glycosylation; 
 Activation of the pro-enzyme; 
 Inhibition by specific inhibitor s (TIMP-1 and TIMP-2); 
 Uptake and internalization by membrane receptors. 
 
Transcription	
Usually, MMPs expression in tissues is low whereas it increases when 
ECM remodeling is required. 
The different response of the genes of MMP-2 and MMP-9 is due to 
differences in the promoter region (Figure 6). In fact, the promoter 
region of MMP-9 gene contains regulatory elements recognized by 
transcription factor induced by growth factors and cytokines, whereas 
MMP-2 has not. For this reason, the MMP-2 gene is considered more 
refractory to modulation by growth factors and cytokines produced 
during inflammation, while MMP-9 can be up-regulated. 
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There are several factors that control the transcription of MMP-9: we can 
distinguish between suppressing factors and inducing factors of the 
enzyme synthesis and they can vary depending on the examined cell type 
(Table 2). 
 
Table 2. Some inducing factors and suppressing factors of MMP-9 synthesis. 
(Van den Steen PE et al., 2002) 
Inducing factors Suppressing factors 
 
EGF (epidermal growth factor), 
PDGF (Platelet derived growth 
factor), bFGF (basic fibroblast 
growth factor), TGF-, 
amphiregulin, TNF-, IL-1, IL-
1, IFN- (interferon-), IFN-, 
TGF-, phorbolic esters. 
 
IFN-, IFN-, IL-4, IL-10. 
In some cell types also IFN-, IL-
1, IL-13, EGF, PMA (phorbol 12-
myristate 13-acetate) and TGF-. 
 
While there are numerous cytokines that can induce MMP-9 synthesis, 
only a small number of them (IL-4, IL-10, IFN- and IFN-) have an 
inhibitory effect on basal or stimulated expression of MMP-9 (Van den 
Steen PE et al., 2002). 
Generally, IFN- and IFN- have an inhibitory effect on MMP-9 
expression, although it has been shown that the treatment of melanoma 
metastatic cells with these cytokines cause an up-regulation of MMP-9 
(Hujanen et al., 1994; Wu et al., 1997). 
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The N-linked glycans in the MMP-9 have a variable composition and can 
have different functions. For example, during the proteolytic cascade that 
leads to MMP-9 activation, the glycosylation is important for the specific 
activity of t-PA and plasminogen. Furthermore, N-linked glycans could 
influence the MMP-9 stability, the resistance to proteases or they could 
modulate the interaction with substrates, inhibitors or with enzymatic 
complexes that degrade the ECM. However, it has been shown that the 
enzymatic activity of MMP-9 does not change after the removal of N-
linked glycans (Rudd PM et al., 1999). 
The majority of the carbohydrates are O-linked (about 85%), and are 
located especially in the collagen V-like domain, typical of this 
metalloproteinase (Figure 8). The analysis of these glycans showed that 
a big variability in its composition exists (Rudd PM et al., 1999).  
Different functions have been hypothesized for these O-linked glycans, 
including protection from proteolysis and increase of the protein stability. 
Moreover, knowing that O-linked glycan clusters increase the extension 
and the rigidity of the polypeptide chain, probably they could contribute 
maintaining the hemopexin-like domain in the correct distance from the 
other domains and favoring the interaction with its specific inhibitor 
(Rudd PM et al., 1999). 
In fact, it has been shown that the deletion of the collagen V-like domain 
decrease 4 times the affinity for TIMP-1, suggesting that this domain is 
essential to maintain the correct space between the C-terminal domain 
and the catalytic one (Van den Steen PE et al., 2006). 
 Figure 8.
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compounds cause the displacement of the sulphidryl group from the zinc 
leading to an early non-proteolytic activation of the enzyme (Van Wart et 
al., 1990). Afterwards, it takes place an auto-proteolytic cleavage of the 
propeptide which leads to the final activation of the enzyme. 
Furthermore, in the MMP-9 has been observed the loss of the 
hemopexin-like domain. 
In addition, MMP-9 can be activated by reactive oxygen species (ROS) 
including hypoclorous acid: this is interesting since neutrophils can 
produce ROS after the respiratory burst activation and they also release 
MMP-9 (Siwik AD et al., 2004). 
 
Activation of proMMP-9 
MMP-9 is synthesized as a 92 kDa proenzyme. As said before, one 
activation way is through the plasminogen/plasmin system, which 
converts the proMMP-3 (or pro-stromelysin-1) to active MMP-3, a 
physiologic activator of proMMP-9 (Ogata Y et al., 1992). 
The activation of MMP-9 by MMP-3 occurs in two subsequent steps: the 
first step is the cleavage of a first portion of the propeptide between the 
residues Glu59-Met60, whereas the second step results in the complete 
removal of the propeptide with a cleavage between the residues Arg106-
Phe107 (Figure 11). The first cut is necessary because the second takes 
place: this suggests that probably the residues are not accessible to MMP-
3 when MMP-9 is still zymogen. 
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Receptors	that	mediate	the	catabolism	of	MMP‐2	and	MMP‐9	
One mechanism that could be important in the regulation of the levels of 
these two proteases is the binding to specific receptors, the low density 
Lipoprotein Receptor-related Protein-1 (LRP-1) and low density 
Lipoprotein Receptor-related Protein-2/megalin (LRP-2/megalin). These 
receptors are abundant in hepatic cells and macrophages: these last are 
one of the major sources of MMP-9 and MMP-2. 
It has been shown that these receptors can bind the MMP-2 in complex 
with trombospondin-2 or TIMP-2, but are not able to bind the free 
enzyme (Hahn-Dantona E. et al., 2001). On the contrary, the LRP-1 and 
LRP-2 receptors can bind the free MMP-9 and its complex with TIMP-1, 
without changing the affinity: this suggests that the site recognized by the 
receptor is on the MMP-9 molecule (Hahn-Dantona E. et al., 2001; Van 
den Steen PE. et al., 2006). Mutagenesis experiments showed that the 
collagen V-like domain is important for the binding to these receptors: its 
deletion decrease 10 times the efficiency of the binding, suggesting that it 
is essential for the correct orientation of the molecule. Moreover, these 
experiments identified in the hemopexin-like domain the binding site to 
the receptors (Van den Steen PE. et al., 2006). Once internalized, the 
protease is degraded within the lysosomes. 
It is clear that this mechanism of MMP-2 and MMP-9 uptake is 
important to regulate the extracellular levels of these two enzymes. In 
fact, it has been observed that many tumours are associated to high levels 
of gelatinases correlating with a low expression of the LRP-1 and LRP-2 
receptors, conferring to the cell a more aggressive behaviour (Hahn-
Dantona E. et al., 2001). 
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Inhibition	
Once MMPs have been secreted and activated into the extracellular 
space, one important mechanism of control on their activity is the 
inhibition. It can take place through non-specific inhibitors, such as α2-
macroglobulina, or by the interaction with specific inhibitors namely 
TIMPs (Tissue Inhibitor of Matrix Metalloproteinase). Up to now, four 
members of TIMPs family have been identified: TIMP-1, TIMP-2, 
TIMP-3 and TIMP-4. All these inhibitors share a high structure 
homology. 
In the primary structure there are 12 conserved cysteines forming 6 
disulfide bridges (Figure 14) essential for the correct folding and 
inhibitory activity of the protein (Murphy G and Willenbrock F, 1995). 
These disulfide bridges define 6 loops in the secondary structure of the 
protein: the first halves are in the N-terminal domain and the second 
halves in the C-terminal domain. These two domains follow an 
independent folding: it has been shown that keeping only the N-terminal 
domain the resulted molecule still has inhibitory activity (Van den Steen 
et al., 2002). Moreover, this suggests that the inhibition is due to the N-
terminal domain. 
However, also the C-terminal domain plays important roles: in fact, it is 
involved in the interaction between the gelatinases and their inhibitors. 
TIMP-1 is a glycoprotein of 28.5 kDa composed by 184 amino acids: the 
glycosylation sites are placed in the first and second loops (Figure 14, 
CHO mark). Moreover, its content in sialic acid is extremely variable 
conferring a heterogeneous charge to the molecule. 
In addition to the inhibitory role on MMP-9 activity, TIMP-1 can also act 
on the MMP-3-mediated proMMP-9 activation: when MMP-3 
concentration is less than TIMP-1, the protease is inhibited and cannot 
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activate proMMP-9. On the contrary, if MMP-3 concentration is greater 
than TIMP-1, proMMP-9 can be activated (Bode et al., 1999). 
TIMP-2 is a protein of 194 amino acids with a molecular weight of 21 
kDa, differing from TIMP-1 for the lack of glycosylation and the 
different sequence alignment of the loop 1. Moreover, TIMP-2 has a 
more extended C-terminal end negatively charged. The presence of this 
negative charge in the C-terminal end seems to be essential for the not-
inhibitory interaction with MMP-2 leading to its activation by MT1-
MMP (Bode et al., 1999). 
Beside the inhibitory effect, TIMPs have also other physiological 
functions like stimulating the growth of keratinocytes and fibroblasts: 
this effect could be due to the inhibition of growth factors degradation 
mediated by MMPs (Van den Steel PE. et al., 2002). 
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Mechanism of inhibition of TIMP-1 and TIMP-2 
The mechanism of interaction of TIMP-1 and TIMP-2 with the 
corresponding MMPs (MMP-9 and MMP-2) follows a general pattern, 
with little variations. 
For both gelatinases there are two sites of interaction with the inhibitor: 
one at high affinity, represented by the hemopexin-like domain with a 
nanomolar Kd, and one at low affinity in the active site of the enzyme, 
with a micromolar Kd. As a general mechanism of interaction, the C-
terminal domain of the inhibitor binds to the C-terminal domain of the 
enzyme, while the N-terminal domains of both molecules interact 
together; this so-defined mechanism provides a 1:1 stoichiometry (Bode 
et al., 1999). 
The forms of MMP-9 and MMP-2 have different dissociation constants 
from the inhibitors, due to different ways of interaction with them (Table 
3; Figure 15). 
 
Table 3. Dissociation constants for active and pro MMP-9. 
(Olson MW et al., 1997). 
 
MMP 
TIMP-1 TIMP-2 
Kd 
(μM) 
Kd 
(nM) 
Kd 
(μM) 
Kd 
(nM) 
proMMP-9 (92 kDa) 7.4 35 - - 
MMP-9 attiva (82kDa) 3.1 23.9 12.7 57.9 
proMMP-2 (72 kDa) - - 0.19 5.2 
MMP-2 attiva (67 kDa) 8.5 28.6 2.7 23.1 
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interaction between the C-terminal domains of the two proteins. In fact, it 
has been shown that the TIMP-2 binds only to the catalytic site (with low 
affinity) of MMP-9, without any interaction between the C-terminal 
domains (figure 15). 
As for the association between proMMP-2/TIMP-2, the ability of TIMP-
1 to bind to proMMP-9 is due to the interaction between the C-terminal 
domains of the two proteins. 
The inhibitors can bind both sites on the active form of the enzymes 
except for the TIMP-2/active MMP-9 interaction, where only the N-
terminal domains are involved (figure 15). 
The inhibitory activity of TIMP-1 and TIMP-2 is due to the interaction of 
the first five amino acids (from Cys1 to Pro5) and the strand C of the 
inhibitor with the enzyme (Bode et al., 1999). 
The first five residues of TIMP bind the active site of MMP mimicking 
the P1-P1’-P2’-P3’-P4’ sites of a possible substrate. 
The Ser68/Val69 residues of TIMP-1 and Ala70/Val71 of TIMP-2 from the 
strand C interact with the S2 and S3 sites on the enzyme in a reverse way 
respect to a substrate (Bode et al., 1999) (Figure 16). 
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Different forms of gelatinases 
We can distinguish different forms of gelatinases, both not active or 
active. 
MMP-2 exists only as monomeric form: a proenzyme of 72 kDa, which 
is not glycosylated; an active form of 62 kDa generated after plasma 
membrane activation with the N-terminal sequence starting at Tyr81. 
Moreover, an additional active species of about 45 kDa was reported, 
with high specific activity (Fridman R et al., 1995). This last form lacks 
the C-terminal domain, which is important for the interaction with its 
inhibitor TIMP-2. Thus, the nature of the active species of MMP-2, 
formed after plasma membrane activation, may regulate enzyme activity 
and inhibition by TIMP-2 (Fridman R et al., 1995). 
Also MMP-9 exists in different forms: a monomer of 92 kDa, 
corresponding to the inactive enzyme, an homodimer of ~220 kDa and an 
heterodimer of ~120-130 kDa bound to the lipocalin-2 or NGAL 
(Neutrophil Gelatinase-Associated Lipocalin; Olson et al., 2000). All 
these forms were identified in different MMP-9-producing cell types, 
both normal or pathological, and in various biological fluids and tissues, 
confirming that both dimers and monomers are physiologically present in 
the human organism. 
Concerning dimerization, it takes place within the cell (Dufour A. et al., 
2010) involving the formation of a disulfide bridge between two 
cysteines of the blade IV of the hemopexin-like domain (Dufour A. et al., 
2010). 
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Connell JP et al., 1994) and might reduce the TIMP-1 binding ability 
(Roeb E et al., 2000). However, up to now this potentially uncontrolled 
MMP-9 active form is not yet evidenced in body fluids. 
 
Inflammatory conditions 
Several evidences exist on the role of MMP-9 in pathological conditions. 
When the failure of regulatory mechanisms occurs, it might lead to 
diminished or excessive production of MMP-9 and subsequently to 
restricted, extensive, or improperly timed degradation of ECM (Van den 
Steen PE et al., 2002). Examples of this pathway are premature rupture of 
amniotic membrane and pathologic bone resorption. Other mechanisms 
of disease induction are inflammation, infection, vascular pathology, 
degeneration and malignancy. 
In particular, MMP-9 has been associated to inflammatory conditions 
playing a dual role: direct, by tissue destruction when its activity is not 
controlled by TIMP-1, or indirect, by generation of an inflammatory 
signal or recruitment of inflammatory cells (Delclaux et al., 1996). 
Its role is well-accepted in neuroinflammatory diseases where the 
impairment of the Blood Brain Barrier (BBB) occurs, such as Multiple 
Sclerosis (MS), Intra Cerebral Hemorrhage (ICH), brain ischemia, as the 
up-regulation of the total enzyme levels were detected, but there are not 
information on the levels of the active form of MMP-9. 
On the other hand, the role of MMP-2 in inflammatory conditions is 
controversial. In fact, MMP-2 has been associated to both tissue damage 
and repair (Itoh T et al., 2002; Yong VW, 2005). 
One evidence of the role of MMP-2 in the repair of injured tissue after 
the onset of inflammation is its ability to process a chemokine, the MCP-
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3 (Monocyte Chemoattractant Protein-3), resulting in a shorter form with 
antagonist activity on receptors that bind the entire MCP-3 or other 
chemokines (McQuibban GA et al., 2000). 
The production of this form causes a variation in the chemotactic 
gradient with a corresponding decrease in the recruitment of other 
inflammatory cells that may produce lytic enzymes such as MMP-9 (i.e. 
monocytes and macrophages). Thus, MMP-2 seems to contribute to the 
resolution of the inflammation, a very important aspect of tissue repair. 
In addition, the TGF-β1, a growth factor that starts the tissue repair, 
stimulates the MMP-2 production but inhibits other MMPs: this could 
contribute to the attenuation of the inflammatory response by decreasing 
pro-inflammatory stimuli (McQuibban GA et al., 2000). 
Therefore, I aimed to evaluate the levels of active MMP-9, active MMP-
2, and their inhibitors TIMP-1 and TIMP-2, in inflammatory pathologies 
in order to clarify the role of the active enzymatic forms as biomarkers of 
inflammation and resolution of the inflammatory process. Furthermore, I 
evaluated the influence of pH environmental changes on MMP-9 release 
from neutrophils, as different pH conditions in tissues are associated with 
different inflammatory status (Trevani AS et al., 1999; Kellum JA et al., 
2004).  
 
Multiple Sclerosis 
Multiple Sclerosis (MS) is a chronic demyelinating inflammatory disease 
which affects the Central Nervous System (CNS), in particular the white 
matter; it is characterized by a progressive loss of myelin and 
oligodendrocytes and axonal damage (Noseworthy JH et al., 2000). The 
etiology of MS is still unknown, although it is thought to be on 
autoimmune base, where the loss of tolerance to one or more unidentified 
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myelin and oligodendrocytes antigens occurs, starting an immune 
response (Noseworthy JH et al., 2000). 
The progressive myelin degradation in several points of the CNS 
expresses as clinical variable symptoms, as the destruction of myelin 
sheaths slows or blocks the transmission of nerve impulses along the 
fibres of the brain and spinal cord (Noseworthy JH et al., 2000). The 
areas of the white matter interested in the removal of the myelin are 
known as demyelination plaques. 
Different clinical subtypes of MS are defined on the basis of the disease 
course (Figure 18): 
o Relapsing-Remitting (RR), which affects the 80 % of the MS 
patients, characterized by the abrupt start of symptoms and acute 
episodes of worsening (exacerbations or relapses), with complete 
or partial recovery. Between these episodes, patients may be 
clinically stable, may experience gradual progression or 
disability, or may undergo to a combination of both (Hauser S et 
al., 2006); 
o Secondary Progressive (SP), in which the RR subtype converts in 
most cases, characterized by gradual progression of disability 
with or without superimposed relapses; 
o Primary Progressive (PP), that accounts for 10-15 % of all the MS 
clinical subtypes and it is characterized by gradual progression of 
disability from disease onset, without superimposed relapses 
(Hauser S et al., 2006). 
 Figure 18
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As the assumption of gadolinium reflects an alteration of the Blood Brain 
Barrier (BBB) due to the ongoing inflammation, the foci with contrast 
enhancement are considered plaques of recent onset where the 
inflammatory process is still active. On the contrary, the lesions without 
contrast enhancement are defined as early onset where the inflammatory 
process is idle (Hawkins et al., 1990). Therefore, MRI is able to detect 
disease activity as clinical examination do but with more sensitivity, 
because the appearance of a enhanced lesion may also occur in the 
absence of relapses or clinical disease activity. This could be due to the 
appearance of the lesion in a brain area “silent” form a functional point of 
view, without causing symptoms. 
Currently, it is thought that MS is caused by the infiltration into the CNS 
of autoreactive CD4+ T helper 1 (Th1) lymphocytes, characterized by the 
production of pro-inflammatory cytokines and directed against myelin 
components (Prat et al., 2005). In normal conditions, these lymphocytes 
encounter a hostile and inhospitable anti-inflammatory 
microenvironment that prevents the starting of any immune reaction. In 
MS, the presence of a chronic inflammation into the CNS triggered by 
the tissue damage converts the microenvironment into a pro-
inflammatory type, characterized by the massive recruitment of 
inflammatory cells and blood proteins into the CNS through the BBB. It 
causes the accumulation of chemical mediators and amplification of the 
tissue damage (Prat et al., 2005). Such mediators are proinflammatory 
cytokines, chemokines and metalloproteases, that facilitate the infiltration 
of other cells like macrophages, CD4+ Th1 and Th2 lymphocytes, B 
lymphocytes and CD8+ T lymphocytes (Opdenakker et al, 2003). These 
cells can increase the tissue damage directly through the cytotoxic action, 
as well as indirectly through the release of soluble products toxic for the 
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myelin and neurons (Opdenakker et al., 2003). Among these molecules, 
MMPs may act directly causing damage to the myelin and axons and 
indirectly by favouring the infiltration of immune cells into the CNS 
through the BBB. Of all the MMPs, an over-expression of MMP-9 not 
counterbalanced by the action of TIMP-1 seems to be a crucial step 
involved in the modulation of the immune and inflammatory responses in 
MS. In fact, an impairment in the MMP-9/TIMP-1 balance towards 
uncontrolled proteolytic activity of MMP-9 may lead to promotion of the 
BBB degradation and to the myelin damage (Opdenakker et al., 2003). 
Thus, the MMP-9 proteolytic activity can favour the recruitment of 
inflammatory cells into the CNS enhancing the ongoing inflammation 
(Opdenakker et al., 2003). Furthermore, the importance of this enzyme in 
MS pathogenesis was confirmed by neuropathological studies observing 
that MMP-9 is expressed by all the cells into the demyelinating lesions 
typical of MS (Lindberg et al., 2001). 
Recently, it has been shown that the variation of active MMP-9, which is 
the only form that exerts the catalytic activity, rather than the total MMP-
9 may be a more appropriate biomarker to monitor the status and course 
of the disease (Fainardi E et al., 2006). In fact, it has been observed that 
the levels of active MMP-9 in serum and cerebrospinal fluid (CSF) of 
MS patients were increased during active state of disease evidenced by 
both clinical examination and MRI investigation (Fainardi E et al., 2006). 
Furthermore, it has been found a decrease in TIMP-1 levels in patients 
with clinical and MRI active state of disease: this is in line with the 
hypothesis of an imbalance towards the proteolytic activity of MMP-9. 
Therefore, the variation in the active MMP-9/TIMP-1 ratio might be used 
as biomarker of disease activity, to monitor the disease course even 
during pharmacological therapy (Fainardi E et al., 2006). 
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Unlike MMP-9 that is predominantly up-regulated during inflammatory 
conditions, MMP-2 is constitutively expressed in the brain (Rosenberg 
GA, 2002). An over-expression of MMP-2 could be both protective and 
harmful in MS (Yong VW, 2005; Yong VW et al., 2007) since MMP-2 
seems to promote tissue repair as well as penetration of CD4+ Th1 cells 
and macrophages across the BBB and myelin and/or axonal injury. 
Contradictory findings have also been found in previous 
neuropathological, CSF, and blood studies in which MMP-2 levels in 
acute and chronic demyelinated lesions as well as in CSF, in serum and 
in peripheral blood mononuclear cells (PBMCs) were increased, 
decreased, or represented in equivalent amounts in MS patients when 
compared to controls (Anthony DC et al., 1997; Lindberg LR et al., 
2001; Avolio C et al., 2003; Kouwenhoven M et al.,2003). 
 
Spontaneous Intra Cerebral Hemorrhage (SICH) 
Within the various forms of stroke, spontaneous cerebral 
intraparenchymal hematoma (Spontaneous Intra Cerebral Hemorrhage, 
SICH) is a relatively common disease which accounts for 10-15% of all 
cerebrovascular strokes, with a worldwide incidence from 10 to 20 cases 
each 100.000 inhabitants increasing with age (Qureshi et al., 2001; Xi et 
al., 2006). Currently, the spontaneous intraparenchymal hematoma is the 
main cause of death and disability worldwide (Qureshi et al., 2001). 
Spontaneous intraparenchymal hematoma is a leakage of blood into the 
brain parenchyma due to the rupture of small penetrating arteries that 
originate from the major intracranial arteries (Figure 20). 
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membrane containing meta-hemoglobin. In the peri-hematomal area the 
edema increases and the reactive astrocytosis appears, consisting of a 
change in the astrocytes shape typical of neuroinflammation. 
4) late sub-acute stage (11th day – 6th week from symptoms onset). At 
hemorrhagic core level the rupture of the erythrocytes’s plasma 
membrane occurs, with the release of meta-hemoglobin. In the peri-
hematomal area starts the reduction of the edema and the appearance of 
gliosis scar in the area next to the hemorrhagic core. 
5) early chronic stage (7th week – 6th month from symptoms onset). In 
the hemorrhagic core starts the accumulation of macrophages containing 
hemosiderin and ferritin, whereas in the peri-hematomal area starts the 
resolution of the edema and the formation of a fibrous capsule next to the 
hemorrhagic core.  
6) late chronic stage (over the 6th moth from symptoms onset). In the 
hemorrhagic core there is the formation of a damaged area containing 
CSF and occurs the accumulation of macrophages in the surroundings, 
whereas in the peri-hematomal area starts the retraction of the glial scar. 
Summarizing, the hemorrhagic core undergoes cell necrosis and hence 
the nervous tissue is irreversibly damaged. Instead, the peri-hematomal 
area is affected by edematous reaction which will be subject to 
resolution; thus, the nervous tissue does not suffer irreversible damage. 
The edema that develops in the peri-hematomal area is accompanied by 
an intense inflammatory response with the passage of fluids from the 
blood to the intrathecal space between nervous cells, and the recruitment 
of inflammatory cells into the brain amplifying the tissue damage. 
Both these situations result in an increased permeability of the BBB, 
which is formed by the tight junctions of brain capillaries and 
perivascular processes of astrocytes (Figure 22). 
 Figure 22
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Studies on animal models have shown that the intracerebral injection of 
MMP-2 produced the opening of the BBB leading to bleeding, whereas 
the co-administration of TIMP-2 reduced this phenomenon (Rosenberg G 
et al., 1992). Other evidence of the role of MMPs were obtained for 
MMP-9 in knockout mice, which showed a small infarct volume and less 
damage to BBB after focal ischemia (Rosenberg G et al., 1997; Tejima E 
et al., 2007). Similar results were obtained in experiments on primates 
which showed an early opening of the BBB after stroke associated to 
increased expression of MMP-2, whereas the hemorrhagic transformation 
was related to increased MMP-9 expression (Heo JH et al., 1999; Chang 
DI et al., 2003).  
The role of MMPs in cerebral ischemia have been studied extensively in 
vitro and using animal models; thus, there is little evidence on their role 
in cerebral haemorrhage in humans. 
Few studies have been conducted to determine the concentration of 
gelatinases and their inhibitors, TIMP-1 and TIMP-2 in plasma of ICH 
affected patients (Alvarez-Sabin J et al., 2004; Ramos-Fernandez M et 
al., 2011). In particular, it has been observed that MMP-9 and TIMP-1 
tended to be overexpressed in the acute phase of the ICH, with higher 
levels of these molecules after 24 hours from symptoms onset (Alvarez-
Sabin J et al., 2004). On the contrary, MMP-2 expression seems to follow 
a biphasic behaviour: in fact, it has been observed a peak in MMP-2 
levels immediately after the onset of ICH and another after one week 
from the onset of ICH (Alvarez-Sabin J et al., 2004). 
Also, a relationship between the overexpression of MMP-9 and TIMP-1 
and different stages of the ICH evolution was observed. In particular, it 
has been shown a positive correlation between MMP-9/TIMP-1 ratio, 
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considered a marker to monitor inflammation, and the volume of the 
edema in the peri-hematomal area (Alvarez-Sabin J et al., 2004). 
Moreover, in another study Abilleira and co-workers found higher 
plasma levels of MMP-9 in patients with ICH, with a relation between 
relative peri-hematomal edema volume and MMP-9 concentration in 
patients with deep ICH (Abilleira S et al., 2003). Indeed, the plasma 
concentrations of TIMP-1 increased regardless of the hematoma 
topography. 
In vitro studies on primary culture of astrocytes from cerebral cortex of 
mice subjected to hemoglobin-mediated oxidative stress to mimic an 
haemorrhage, showed that MMP-9 concentration increased within one 
hour after the oxidative stress exposure in a dose-dependent manner, and 
the concentration was maintained up to 24 hours (Tejima E et al., 2007). 
Instead, no substantial changes of MMP-2 levels were observed. 
To date, no quantitative data on serum levels of active form of MMP-9 
and MMP-2 in patients with spontaneous cerebral hematoma exist. 
 
Neutrophils and changes in environmental pH  
There is a growing body of evidence that acid-base abnormalities are 
capable to induce significant alterations on the immune response. In fact, 
it has been observed that changes in the extracellular pH can affect the 
synthesis and the release by cells of the immune system of pro-
inflammatory mediators, such as tumor necrosis factor (TNF) and nitric 
oxide (NO) (Kellum JA et al., 2004). 
Furthermore, it has been shown that different acids (HCl [hydrochloric 
acid], lactic acid and lactate solutions) may produce different effects 
(increase or decrease in the levels of the mediators) despite the same 
extracellular pH. In particular, it appears that the HCl act as pro-
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inflammatory agent, while the lactic acid appears to be an anti-
inflammatory agent (Kellum JA et al., 2004). 
Extracellular acidosis can also affect other aspects of the immune 
response, such as extreme acidity (pH between 6.0 and 5.5) causes 
dysfunction in the chemotactic process of leukocytes (Nahas GG. et al., 
1971). 
Among all leukocytes, neutrophils are the most abundant type of white 
blood cells in mammals and form an essential part of the innate immune 
system. Although they play an important role in host defense against 
infectious agents, they may also cause tissue damage in a wide range of 
diseases (Weiss SJ, 1989), where the tissue-damaging effects of 
neutrophils are completely dependent on the activation of degranulation 
(Cundall M et al., 2003; Lacy P et al., 2008). 
Degranulation is defined as the secretion by receptor-mediated 
exocytosis of granule-derived substances. Granules of neutrophils may be 
classified from a functional point of view into peroxidase-positive (or 
azurophilic or primary) granules, defined by their content of 
Myeloperoxidase (MPO), and peroxidase-negative granules. The latter 
can be further subdivided into specific (or secondary) granules, defined 
by their content of lactoferrin, and gelatinase (or tertiary) granule, 
defined by their high concentration of gelatinase B (MMP-9) (Figure 23) 
(Borregard N et al., 1997).  
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Such microenvironments may develop as a result of several factors 
(Martinez D et al., 2006): 
 lowering of the oxygen partial pressure in the inflamed area 
(hypoxia) and the intense metabolic activity of inflammatory cells 
that switch from aerobic to anaerobic metabolism (glycolysis), 
leading to the accumulation of lactate; 
 massive infiltration of neutrophils and macrophages and the 
production of protons during the respiratory burst activation; 
 the accumulation of short-chain fatty acids produced by bacteria. 
Extracellular acidification induces several changes in neutrophils, both 
functional and structural. It was observed that the levels of intracellular 
calcium increased significantly in neutrophils stimulated in acidic pH 
(6.5) compared to physiological pH (7.4) (Trevani AS et al., 1999). In 
addition, neutrophils change their shape in response to extracellular 
acidification. Two mechanisms have been proposed to explain such 
modification: 
1. a reorganization of the cytoskeleton leading to disassembling of 
actin polymers in monomers; 
2. activation of the Na+/H+ antiport causing the cell swelling due to 
the movement of ions and the entry of water into the cell. It has 
been shown that the activation of this antiport is necessary for the 
efficient migration of neutrophils (Rosengren S et al., 1994). 
Another effect of acidic pH is the up-regulation of receptors which 
promote the adhesion of neutrophils to the endothelium, such as the β2 
integrin (CD18) (Trevani AS et al., 1999). 
Considering that the changes in neutrophils shape and adhesive 
interactions with endothelial cells are essential steps for the migration to 
the sites of inflammation, this suggests that acidic extracellular pH can 
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promote the recruitment of neutrophils in inflammatory areas (Trevani 
AS et al., 1999). 
Moreover, low extracellular pH can trigger the production of H2O2 and 
the release of myeloperoxidase (marker of degranulation and oxygen-
dependent cytotoxic response) from neutrophils stimulated with different 
agonists (Trevani AS et al., 1999).  
However, other studies have shown conflicting results about the effect of 
extracellular acidosis on neutrophil responses. In particular, it has been 
postulated that extracellular acidosis can have a negative effect on 
neutrophils bactericidal activity. In fact, extracellular acidosis can 
activate the G protein-coupled receptor TDAG8 (T cell death-associated 
gene 8) leading to an increase in cAMP concentration that induce the 
inhibition of superoxide anion (O2-) production (Murata N et al., 2009). 
Two mechanisms for the action of pH on neutrophils have been 
proposed: the change in intracellular pH and the stimulation of proton-
sensing receptors. 
Acidification of the cytoplasm could be due to the diffusion of CO2 into 
the cell causing an increase in intracellular protons. Therefore, the 
extracellular pH decrease can act as a second messenger in the activation 
of neutrophils. In particular, it has been observed that initial stages of 
chemotaxis are accompanied by transient cytosolic acidification (Yuli I. 
et al., 1987). 
Another hypothesis is that extracellular acidosis can influence 
neutrophils through the activation of specific proton-sensing receptors 
expressed on the surface membrane surface. 
Recent studies have shown that protons can be recognized by a subfamily 
of G protein-coupled receptors, namely GPR4. This subfamily consists of 
four receptors with high sequence homology: GPR4 (G protein-coupled 
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receptor 4), OGR1 (ovarian cancer G protein-coupled receptor 1), 
TDAG8 (T cell death-associated gene 8) and G2A (for G2 
accumulation). 
Extracellular pH changes are able to activate different pathways 
depending on the receptor involved: the activation of OGR1 and G2A 
leads to the accumulation of inositol phosphate, whereas the activation of 
GPR4 and TDAG8 leads to the formation of cyclic AMP (cAMP) 
(Martinez D et al., 2006). 
In vitro experiments on HL-60 neutrophil-like cells and human 
neutrophils have shown that the G protein-coupled receptor mainly 
expressed is the TDAG8, followed by OGR1 and G2A, whereas the 
GPR4 is not expressed (Murata N et al., 2009). 
Although the real mechanism responsible for the recognition of 
extracellular protons remains to be elucidated, it was shown that 
extracellular acidosis activates the signal transduction pathways that 
involve the phosphoinositide 3-kinase (PI3K)/Akt and ERK (Martinez D 
et al., 2006). Such signaling pathways play an important role in several 
neutrophils functions: in fact, both PI3K and ERK are required for the 
activation of chemotaxis, phagocytosis, respiratory burst and are also 
implicated in the control of survival (Andrews S et al., 2007). 
 
Neurofilament subunits and N-Acetyl aspartic Acid (NAA) 
as markers of axonal damage in progressive multiple 
sclerosis 
As previously reported, different clinical subtypes of MS are defined 
(Lublin FD et al., 1996), for which Primary Progressive (PP) MS 
accounts for 10-15% of all the MS clinical subtypes (Miller DH et al., 
2007). 
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The classification of the disease subtype is highly relevant because 
disease-modifying treatments are effective only in predominantly 
relapsing MS (Miller DH et al., 2007). In fact, focal inflammatory lesions 
are the main features of relapse-onset MS (RRMS), whereas the 
progressive form of the disease (PPMS) is characterised by a global 
inflammatory process, with diffuse axonal injury in white matter and 
cortical demyelination (Kutzelnigg A et al., 2005). This is confirmed by 
the observation of extensive cortical demyelination and diffuse damage 
with microglial activation and axonal injury in the healthy-looking white 
matter of patients with PPMS (Kutzelnigg A et al., 2005). Moreover, 
Revesz and colleagues (Revesz T et al., 1994) reported few inflammatory 
cells in lesions of PPMS patients: this finding, combined with early MRI 
studies that showed fewer focal white-matter lesions in PPMS patients 
(Thompson AJ et al., 1990), led to the notion that pathological features 
additional to classic inflammatory, demyelinating, white-matter lesions 
might be important for the disability in PPMS. 
There is a strong evidence that axonal loss underlies irreversible and 
progressive disability, which has led to the search for potential 
biomarkers of axonal damage for use in in-vivo studies. 
CSF N-acetylaspartate (NAA) as well as Neurofilaments (Nf) light and 
heavy subunit levels were recently identified as promising markers of 
axonal damage in MS patients (Teunissen CE et al., 2009). 
 
Neurofilaments 
Neurofilaments (Nf) are neuron-specific proteins that have emerged as 
promising biomarkers for neurodegeneration, especially the Nf light and 
Nf heavy subunits (Rosengren LE et al., 1996; Norgren N et al., 2003; 
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A growing body of evidence points to Neurofilament light and heavy 
subunits as surrogate markers for axonal injury in MS. 
The light subunit has been related to early phases of MS and even as a 
prognostic marker in early relapsing-remitting MS (Salzer et al., 2010). 
In particular, Salzer and colleagues determined in a long-term follow-up 
study the Nf light levels in CSF of RRMS patients. Their findings 
associated high CSF Nf light levels with unfavourable prognosis, 
suggesting that the levels of this subunit could be used as a prognostic 
marker in early RRMS. Moreover, neurofilament light has been recently 
used as a marker to monitor the neuroprotective effect of Natalizamab, a 
disease-modifying treatment (Gunnarsson M et al., 2010). In their study 
Gunnarsson et al found a 3-fold reduction of Nf light levels after the 
treatment with the drug, suggesting that Natalizumab can reduce the 
accumulation of nerve injury in relapsing form of MS (Gunnarsson M et 
al., 2010). Also, the neurofilament heavy subunit has been shown to be 
related to disease progression (Petzold A et al., 2005a). In fact in their 
follow-up study, Petzold and colleagues found that patients with 
Secondary Progressive (SP)/PPMS experienced an increase in Nf heavy 
levels between baseline and follow-up compared with those with RRMS. 
Moreover, Nf heavy levels were higher in SP/PPMS patients than RRMS 
both at baseline and follow-up. Interestingly, they also found a positive 
correlation between neurofilament high levels and the EDSS (Expanded 
Disability Status Scale). All their results suggest that cumulative axonal 
loss is responsible for sustained disability and that high Nf heavy levels 
are a poor prognostic sign of MS progression (Petzold A et al., 2005a). 
Collectively taken, these results point to neurofilament light and heavy 
subunits as markers of axonal damage in MS. 
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NAA 
A proposed in vivo marker for axonal pathology in MS is N-Acetyl 
Aspartic Acid (NAA). 
NAA is an amino acid present in the vertebrate brain, where its 
concentration is one of the highest of all free amino acids and it 
constitutes about 3–4 % of total brain osmolarity (Baslow MH, 2000). 
NAA is synthesized primarily in neurons being present in amounts up to 
20 mM and exhibiting a high intracellular-extracellular gradient. Further, 
neuronal NAA is dynamic in that it turns over about 1.4 times per day 
(Moreno A et al., 2001) by virtue of its continuous efflux in a regulated 
intercompartmental cycling via extracellular fluids between neurons and 
a second compartment in oligodendrocytes (Baslow MH, 2002). 
Post-mortem investigation of spinal cords from MS patients has shown 
that lower tissue concentrations of NAA are related to lower axonal 
volume. Furthermore, the average NAA concentration per axonal volume 
may decrease with increasing demyelination and functional impairment 
of neurons (Bjartmar C et al., 2000). 
MR-spectroscopy (MRS) is widely used to determine parenchymal NAA 
concentrations in vivo. Clinical studies employing MRS (Bruhn H et al., 
1992; Leary SM et al., 1999) universally show decreased NAA levels 
associated with the progression of the disease. Reduced amounts of NAA 
in MR-visible lesions and in normal appearing white matter are readily 
documented (Leary SM et al., 1999): these MRS observations are 
explained as axonal injury (Criste GA and Trapp BD, 2006). Axonal 
injury begins early in multiple sclerosis (De Stefano N et al., 2002), and 
cumulative axon loss results in progressive disability.  
MRS studies show that NAA levels can be associated with neuronal 
dysfunction, as well as neuronal death, because levels have been shown 
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to recover when MRI visible plaques resolve (Arnold DL et al., 1990). 
Partial recovery of NAA levels has also been reported after treatment of 
patients with disease-modifying treatments (Narayan S et al., 2001) 
suggesting that NAA levels reflect not only neuronal and axonal 
integrity, but also may reflect improvements in neuronal energetics and 
possibly remyelination (Moffet JR et al., 2007). 
Moreover, recent studies showed that CSF NAA levels are related to 
disease progression and brain atrophy (Jasperse B et al., 2007; Teunissen 
CE et al., 2009). In particular, it has been observed that SPMS patients 
had a significantly lower NAA concentration than RRMS patients 
(Jasperse B et al., 2007), whereas the levels were not different from 
patients without neurologic disease in early stages of disease, though 
decreased as the disease progressed (Teunissen CE et al., 2009). 
Furthermore, NAA concentrations correlated with EDSS, normalised 
brain volume and MRI measures of disease burden. Therefore, these 
studies suggest that NAA may be an important neuron specific marker of 
disease severity and possibly progression. 
Recently, the combination of CSF N-acetylaspartate (NAA) and 
neurofilament light and heavy subunit levels has increased the potential 
to identify patients with axonal damage (Teunissen CE et al., 2009). Up 
to now, little is known about the relevance of Nf isoforms and NAA as 
markers of disease in the PPMS subtype. In fact, while Nfs have been 
extensively studied in the RRMS and SPMS (Teunissen CE et al., 2005), 
a lack of reliable data still remains for the PPMS subtype where small 
cohorts were studied and often pooled together with SPMS patients 
(Semra YK et al., 2002; Norgren N et al., 2003). Similarly, different 
levels of CSF NAA were found only in RRMS and SPMS patients but 
not in PPMS subtype compared to non-diseased controls, but also here 
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the studies included small cohorts of primary progressive patients (n=6-
8) (Jasperse B et al., 2007; Teunissen CE et al., 2009). 
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AIMS OF THE THESIS 
 
Actually, the role of gelatinases in inflammation seems to be opposite.  
MMP-2 has been related to both tissue repair and damage, although its 
role is not yet clear; on the contrary, MMP-9 which can be produced also 
by neutrophils, has been associated to inflammation in several 
pathologies. Also, the environmental conditions such as acidosis and 
alkalosis might influence the release of MMP-9 from neutrophils. 
Furthermore, the possible presence in body fluids of another active form 
of MMP-9, which might not be modulated by its inhibitor TIMP-1, could 
open new insights on the use of active MMP-9 as biomarker in 
inflammation. 
In the present thesis, I aimed to evaluate the role of active MMP-9 and 
MMP-2 as biomakers in inflammatory conditions such as Multiple 
Sclerosis and in Spontaneous Intra Cerebral Hemorrhage; also, I aimed to 
investigate the presence in serum of the 66 kDa MMP-9, and pH effect 
on the neutrophils response since low tissue pH has been associated to 
inflammation. 
Secondary, my purpose was to study the role of Nf light and heavy 
subunits, NAA and their combination as biomarkers of axonal damage in 
a relatively large cohort of PPMS, since the combination of 
neurofilaments and NAA were identified as promising markers of axonal 
degeneration in MS patients. 
The final target is to verify if the use of different biomarkers, which 
reflect various aspects of pathological processes, and their combination 
could be useful in order to predict the evolution of a disease. 
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MATERIAL AND METHODS 
 
Active MMP-2 and TIMP-2 in Multiple Sclerosis Patients 
 
Patient selection 
A total of 67 consecutive patients (45 women and 22 men; mean age = 
37.3 ± 10.2 years) meeting the criteria for definite MS according to the 
classification of McDonald et al. (McDonald WI et al., 2001) and 
admitted to the MS Center of the Department of Neurology, University 
of Ferrara during the period from October 2004 to January 2008 were 
prospectively recruited in the study. All patients had relapsing–remitting 
(RR) course in agreement with the criteria of Lublin and Reingold 
(Lublin and Reingold, 1996). Evidence of a relapse at admission, as 
defined by Poser’s criteria (Poser CM et al., 1983), was considered 
clinical disease activity. Accordingly, at entry 44 patients were clinically 
active and 23 were clinically stable. Disease severity was scored in all 
MS patients at the time of sample collection using Kurtzke’s Expanded 
Disability Status Scale (EDSS) (Kurtzke JF, 1983) (mean at entry = 2.1 ± 
1.2; range from 0 to 5.5). The duration of the disease was expressed in 
months (mean at entry = 36.8 ± 58.4; range from 0.5 to 300). At entry, 
none of the patients had fever or other symptoms or signs of acute 
infections. Moreover, at the time of inclusion in the study none of the 
patients had received any potential disease-modifying therapies (e.g., 
azathioprine or methylprednisolone, interferon-beta or glatiramer acetate) 
during the six months before the study. In all, 64 patients with other 
inflammatory neurological disorders (OIND) and 65 subjects with other 
non-inflammatory neurological disorders (NIND) were selected as 
neurological controls. The OIND group (33 women and 31 men, mean 
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age = 52.5 ± 17.5 years) included 13 patients with viral 
encephalomyelitis, 12 with chronic inflammatory demyelinating 
polyneuropathy, 10 with acute inflammatory demyelinating 
polyneuropathy, 8 with bacterial meningitis, 6 with HIV encephalopathy, 
5 with intracerebral abscess, 4 with neurolupus, 3 with acute 
demyelinating encephalomyelitis, 2 with neuroSjogren, and 1 with 
Neurobehcet. The NIND group (28 women and 40 men, mean age = 54 ± 
15 years) consisted of 10 patients with headache, 9 with migraine, 7 with 
transient ischemic attack, 7 with epilepsy, 6 with cervical spondylosis, 5 
with vascular dementia, 5 with mild cognitive impairment, 4 with 
Alzheimer’s disease, 4 with hereditary ataxia, 2 with amyotrophic lateral 
sclerosis, 2 with compression neuropathy, 2 with paresthesias, 1 with 
confusion, and 1 with vascular myelopathy. Patients with OIND and 
NIND were free of immunosuppressant drugs, including steroids, at the 
time of sample collection. 
 
Cerebrospinal fluid and serum sampling 
Cerebrospinal fluid and serum samples were collected under sterile 
conditions and stored in aliquots at −70°C until assay. “Cell-free” CSF 
samples were obtained after centrifugation at room temperature of 
specimens taken by atraumatic lumbar puncture performed for purposes 
of diagnosis in the absence of contraindications. Serum samples derived 
from centrifugation of blood specimens withdrawn by puncture of an 
anterocubital vein at the same time of CSF extraction. Paired CSF and 
serum samples from RRMS, OIND, and NIND patients were stored and 
measured under exactly the same conditions. All CSF and serum analysis 
were performed within 2 weeks of the onset of clinical symptoms in 
relapsing RRMS patients and at least 2 months after the end of clinical 
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exacerbation in clinically stable RRMS patients. Informed consent was 
given by all patients before inclusion, and the study design was approved 
by the Regional Committee for Medical Ethics in Research. 
Cerebrospinal fluid and serum albumin levels were measured by 
immunochemical nephelometry with the Beckman Array Protein System 
(Beckman Instruments, Inc. Fullerton, California, USA) according to the 
procedure in the study by Salden et al. (Salden HJM et al.,1988). Blood-
CSF-barrier (B-CSF-B) dysfunction was determined by CSF/serum 
albumin quotient (QAlb) (Tibbling G et al., 1977). 
 
Magnetic resonance imaging examination 
Brain magnetic resonance imaging (MRI) scans were performed at entry 
using a standard head coil in all patients with a 1-tesla MRI unit (GE 
Signa Horizon, General Electric Medical Systems, Milwaukee, 
Wisconsin, USA) within 48 h after CSF sampling. Routinely used T1-
weighted axial spin echo images were obtained approximately 10 min 
after intravenous injection of 0.1mmol/kg of gadolinium (Gd)-DTPA in 
each patient. Lesions showing Gd- enhancement on T1-weighted scans 
were defined as indicative of MRI activity. Accordingly, 33 MS patients 
(26 with clinically active and 7 with clinically stable disease) were 
considered MRI active and 34 (19 with clinically active and 15 with 
clinically stable disease) were considered MRI inactive. All brain MRI 
scans were evaluated by one investigator (EF) blinded to clinical and 
sample data. 
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MMP-2 activity assay 
Cerebrospinal fluid and serum concentrations of active MMP-2 were 
measured by a commercially available Activity Assay System kit 
(Activity Assay System, Biotrak, Amersham Biosciences, Little 
Chalfont, UK, Cat. N. RPN 2631) according to the manufacturer’s 
instructions. All reagents and standards were included in the kits. Briefly, 
undiluted CSF or serum diluted 1:100 were analysed in duplicate into 96-
microwell microtiter plates pre-coated with anti-MMP-2 antibody. Six 
serial dilutions of standard were dispensed on each plate in duplicate with 
a range of 0.19–6 ng/mL. After an overnight incubation at 2–8°C and 
four washing cycles, only the enzyme had bound to the wells. The 
standard, a human pro-MMP-2, was activated by adding 50 μL/well of p-
aminophenylmercuric acetate (APMA). In parallel, to detect endogenous 
levels of active MMP-2, 50 μL of dilution buffer was dispensed into each 
well instead of APMA. At the same time, 50 μL of the detection reagent 
was pipetted into each well. The amount of active MMP-2 was 
determined by interpolation from the standard curve. Cerebrospinal fluid 
and serum samples with concentrations outside the range of 
determination were re-assayed at greater dilutions to obtain values falling 
into the standard curve. The lower limit of quantification of the assay was 
0.19 ng/mL, the range of intra-assay coefficient of variations (CV) was 
4.4–7.0%, whereas the range of inter-assay CV was 16.9–18.5%. 
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TIMP-2 ELISA assay 
Cerebrospinal fluid and serum levels of TIMP-2 were measured by using 
a commercially available “sandwich” ELISA kit (Biotrak, Amersham 
Bio- sciences, Little Chalfont, UK, Cat. N. RPN 2618) according to the 
manufacturer’s instructions. Both CSF and corresponding serum samples 
were diluted at 1:4. The limit of sensitivity of the assay was 3 ng/mL. 
 
Determination of total and active MMP-2 and TIMP-2 Indices 
According to the IgG index (Tibbling G et al., 1977), intrathecal 
production of active MMP-2 and TIMP-2 was calculated using the 
following formula: 
 
MMP-2 Index = CSF/serum MMP-2: CSF/serum albumin  
TIMP-2 Index = CSF/serum TIMP-2: CSF/serum albumin 
 
where the ratio between CSF and serum albumin concentrations 
represents the status of B-CSF-B. Intrathecal synthesis was assumed for 
values greater than 3 SD above the mean of NIND. 
 
Statistical analysis 
The normality of each variable was checked by using the Kolmogorov–
Smirnov test. When normality of data distribution was found in all 
variables, statistical analysis was performed by a parametric approach. 
Conversely, when normality of data distribution was rejected in several 
variables, a non-parametric analysis was applied. Accordingly, serum 
mean concentrations of active MMP-2 and CSF mean levels of TIMP-2 
were compared by using (a) ANOVA, followed by Scheffè test, among 
RRMS, OIND, and NIND and (b) t-test between RRMS patients grouped 
67 
 
according to clinical and MRI activities. In contrast, CSF mean levels of 
active MMP-2, serum mean concentrations of TIMP- 2, and CSF and 
serum mean values of active MMP-2/TIMP-2 ratio were compared by 
means of (a) Kruskal–Wallis test, followed by Mann–Whitney U-test 
with Bonferroni correction for multiple comparisons, among RRMS, 
OIND, and NIND and (b) Mann–Whitney U-test between RRMS patients 
classified according to clinical and MRI activities. Chi-square test was 
used to compare the patient group percentages of intrathecal synthesis of 
MMP-2 and TIMP-2, as indicated by the presence of specific Index 
abnormal values. In cases of multiple comparisons, a Bonferroni post hoc 
was applied. As normality of data distribution was not detected in several 
MS variables, possible relationships among them were assessed by using 
the Spearman’s rank correlation coefficient test. A value of p<0.05 was 
considered statistically significant. 
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Active gelatinases and TIMPs in SICH 
 
Patient selection 
Twenty-eight patients (18 males and 10 females; mean age ± SD = 71.4 ± 
10.8 years) with diagnosis of acute supratentorial SICH proven by 
admission non-enhanced computed tomography (CT) scan carried out 
within 24 hours of onset were prospectively included in the study. Time 
of onset was considered as the last time the patient was known to be 
neurologically normal. Exclusion criteria at the time of enrollment were: 
1) occurrence of infratentorial hemorrhage; 2) hematoma related to 
tumor, trauma, coagulopathy, aneurysms, vascular malformations; 3) 
hemorrhagic transformation of brain infarction; 4) intraventricular 
extension of hemorrhage; 5) surgical hematoma evacuation performed 
after the first non-contrast CT scans; 6) age < 20 years; 7) evidence of 
pregnancy. Disease severity was scored in all patients using the National 
Institutes of Health Stroke Scale (NIHSS) [3] at 24 hours (admission), 48 
hours and 7 days (follow-up) from onset. 
 
CT examination 
All CT scans were performed by using a single-section CT scanner (CT 
HiSpeed ZX/i; GE Medical System, Milwaukee, Wis) at the same time 
points as NIHSS calculation: 24 hours (baseline), 48 hours and 7 days 
(follow-up) after bleeding. Based on their location, hematomas were 
classified as basal ganglia and lobar. Accordingly, SICH was located 
within basal ganglia regions in 18 patients and within lobar regions in the 
remaining 10 patients. Hematoma volume was calculated at non-
enhanced initial CT scan using the formula AxBxC/2 where A, B and C 
represent the dimensions of CT hyperdensity in 3 axes perpendicular to 
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each other (Kothari RU et al., 1996). The volume of hematoma plus that 
of perihematomal low density area was determined with the same 
method. Perihematomal edema volume was measured by subtracting the 
hematoma volume from the combined hematoma and perihematomal low 
density area volumes. Hematoma expansion was defined as a volume 
increase > 33% between the baseline CT scan obtained at 24 hours and 
the follow-up CT scan performed at 48 hours (Brott T et al., 1997). 
Informed consent was obtained from each patient or from his close 
relatives before the CT was performed. 
 
Serum sampling 
Serum samples were obtained from centrifugation at room temperature of 
blood specimens previously withdrawn by puncture of an anterocubital 
vein collected under sterile conditions at the same time points as NIHSS 
calculation and CT scan performance: 24 hours (baseline), 48 hours and 
7 days (follow-up) after SICH. Serum specimens were then stored in 
aliquots at –70°C until assay. 
 
MMPs activity assays and TIMPs assays 
As reported previously (Fainardi E et al., 2006), serum concentrations of 
active MMP-9 and MMP-2 were measured by using commercially 
available Activity Assay System kits (Activity Assay System, Biotrak, 
Amersham Biosciences, UK, MMP-9 Cat. N. RPN 2634; MMP-2 Cat. N. 
RPN 2631) according to the manufacturer’s instructions, with a sample 
dilution of 1:20 for MMP-9 and 1:100 for MMP-2 determinations. The 
lower limit of quantification was 0.125 ng/ml for MMP-9 and 0.19 ng/ml 
for MMP-2. 
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Serum levels of TIMP-1 and TIMP-2 were measured by using 
commercially available “sandwich” enzyme-linked immunosorbent assay 
(ELISA) kits (Biotrak, Amersham Biosciences, UK; TIMP-1 Cat. N. 
RPN 2611; TIMP-2 Cat. N. RPN 2618) according to the manufacturer’s 
instructions. Serum samples were diluted at 1:40 for TIMP-1 and at 1:4 
for TIMP-2 determinations. The limit of sensitivity of the assay was  3 
ng/ml for both TIMP-1 and TIMP-2. 
 
Statistical analysis. 
After checking data for normality by using the Kolmogorov-Smirnov 
test, repeated measures ANOVA followed by post-hoc Scheffè test, 
Friedman ANOVA followed by post-hoc Mann-Whitney test, Spearman 
rank correlation coefficient test and linear regression analysis were used 
when appropriate. A value of p<0.05 was considered as statistically 
significant. 
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Detection of 66 kDa active MMP-9 in Serum 
 
Blood specimen collection and storage 
Serum samples from 28 healthy volunteers (12 female and 16 male; mean 
age ± SD = 32.4 ± 8.2 years) were collected in VacutainerTM tubes and 
centrifuged within 30-60 minutes after venipuncture at 3000 rpm for 12 
minutes at room temperature. After removal of the supernatants, serum 
samples were aliquoted and stored at –80°C until assay. Each sample was 
analysed in duplicate in the same session. Serum specimens were chosen 
since active MMP-9 concentrations are not altered by clotting 
phenomena that take place in collector tubes (Fainardi E et al., 2007; 
Castellazzi M et al., 2007). Informed consent was given by all volunteers 
before inclusion and the study design was approved by the Local 
Committee for Medical Ethics in Research. 
 
Enzymes, antibodies and reagents 
In all experiments, recombinant human MMP-2 and MMP-9 proenzymes 
used as standards as well as APMA and buffers, were included in 
commercially available Activity Assay System kits (Activity Assay 
System, Biotrak, Amersham Biosciences, UK, Cat. N. RPN 2631 and 
Cat. N. RPN 2634). In preliminary experiments, MMP-9 and MMP-2 
proenzymes were tested for the presence of MMP-2 and MMP-9, 
respectively, with MMP-2 and MMP-9 activity assays. No contamination 
was found in either experiments. TIMP-1 was purchased from Sigma-
Aldrich (Sigma-Aldrich, Milan, Italy, Cat. N. T8947). Concanavalin A 
(ConA) Sepharose and Protein G Sepharose were purchased from Sigma-
Aldrich (Sigma-Aldrich, Milan, Italy, Cat. N. C9017 and Cat. N. P3296 
respectively). Tris Base was purchased from Merck (VWR International, 
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Milan, Italy,); Sodium Chloride, Calcium Chloride, Zinc Chloride, 
BRIJ™ 35 and Comassie Blue-R were purchased from Sigma-Aldrich 
(Sigma-Aldrich, Milan, Italy). The Assay Buffer used for 
immunoprecipitation and activation of MMP-9 was composed as follows: 
50 mM Tris-HCl buffer pH 7.6 containing 1.5 mM Sodium Chloride, 0.5 
mM Calcium Chloride, 1 μM Zinc Chloride and 0.01% (v/v) BRIJ™ 
35. 
 
Gelatin Zymography 
Zymographic patterns of gelatinases were evaluated by using the method 
described by Heussen and Dowdle (Heussen and Dowdle, 1980) on 
gelatin-copolymerized gel. Briefly, samples were applied without 
reduction and boiling to a 10% polyacrylamide gel containing 0,1% 
gelatin. Gel electrophoresis was performed with these settings: 30 mA, 
35W and 450 V/h for about 45 minutes. Then electrophoresis gels were 
incubated with 2.5% (v/v) Triton for 20 minutes three times and then in 
50 mM Tris, pH 7.6, containing 150 mM NaCl, 5 mM CaCl2 and 0.02% 
(v/v) Brij 35 for 22 hours. The gels were then stained with 0.3% 
Comassie Blue-R. 
 
Densitometric analysis of the zymographic patterns 
Gel was scanned using a Canon scanner (CanoScan D660U) interfaced 
with a Windows PC and acquired with Adobe Photoshop (Adobe System 
Inc., Mountain View, CA, USA) in grey scale mode at 600 dpi. The 
corresponding images were saved to disk in TIFF format and then 
analysed using Quantity One® software (Bio-Rad Laboratories). The 
bands were manually selected using the volume tool within the program 
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and their densitometric values were adjusted for the background, giving 
an integrated density reported in volume units of pixel intensity X mm2. 
 
MMP-9 activity assay 
Active forms of MMP-9 were measured using a commercially available 
activity assay system (Activity Assay System, Biotrak, Amersham 
Biosciences, UK, Cat. N. RPN 2634) following the manufacturer's 
instructions. Briefly, each sample was analysed in duplicate into 96 
microwell microtiter plates precoated with anti-MMP-9 antibodies. Six 
serial dilutions of standard were dispensed on each plate in duplicate in 
the range of 0.125 - 4 ng/ml. After an overnight incubation at 2–8 °C and 
four washing cycles, only the enzymes had bound to the wells. The 
standards, human pro-MMP-9, were activated by adding 50 μl/well of 
APMA. In this way, total amounts of MMP-9 were measured. 
Conversely, to detect only endogenous levels of active MMP-9, 50 
μl/well of dilution buffer, instead of APMA, was dispensed into each 
well. Fifty μl of detection reagent, was pipetted into each well. The 
amount of active MMP-9 in all samples was determined by interpolation 
from the standard curve. As reported in the manufacturer’s instructions, 
the lower limit of quantification was assumed at 0.125 ng/ml, the range 
of intra-assay CV was 3.4–4.3%, whereas the range of inter-assay CV 
was 20.2–21.7%. The MMP-9 activity assay was not able to distinguish 
between the two active MMP-9 forms, but only detected both MMP-9 
activities. 
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MMP-9 inhibition by TIMP-1 
Inhibition of MMP-9 by TIMP-1 was measured by slight modification of 
the above mentioned activity assay. Briefly, after an overnight incubation 
of the samples in microtiter plates precoated with anti-MMP-9 
antibodies, 100 μl/well of TIMP-1 (100 ng/ml) were added to all samples 
in order to inhibit the 82 kDa MMP-9 active form. After 90 minutes of 
incubation at 37°C and three cycles of washing the detection reagent was 
applied, and the residual MMP-9 activity was assigned to 66 kDa active 
MMP-9. The optimal concentration of TIMP-1 used for these 
determinations was tested in preliminary experiments which showed that 
higher concentrations of TIMP-1 did not cause a further decrease in 
MMP-9 activity (data not shown). 
 
MMP-2 activity assay 
Active forms of MMP-2 were measured using a commercially available 
activity assay system (Activity Assay System, Biotrak, Amersham 
Biosciences, UK, Cat. N. RPN 2631) as previously reported. According 
to the manufacturer's instructions, the lower limit of quantification of the 
assay was 0.19 ng/ml, the range of intra-assay coefficient of variations 
(CV) was 4.4–7.0%, whereas the range of inter-assay CV was 16.9–
18.5%. 
 
Activation of pro-MMP-9 
A sample of recombinant human MMP-9 (8 ng/ml) was incubated with 1 
mM APMA (diluted in Assay Buffer) at 37 °C up to six hours in order to 
activate the enzyme. Samples were withdrawn from the incubation 
mixture at baseline, two, four and six hours. Then, the samples were 
incubated overnight at 4 °C in microtiter plates precoated with anti-
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MMP-9 antibodies to test by activity assay with and without TIMP-1, or 
kept at 4° C overnight and assayed by gelatin zymography. 
 
Immunoprecipitation 
To identify the 66 kDa MMP-9 from a serum sample, a two-step 
immunoprecipitation procedure was conducted by using monoclonal 
antibody against MMP-9 (R&D Systems, Minneapolis, MN, USA, Cat. 
N. MAB936). As indicated by the manufacturer’s instructions, this 
antibody is able to bind pro (92 kDa) and active (82 kDa) forms of 
recombinant human MMP-9, but it does not react with the C-terminal 
truncated form (66 kDa) of MMP-9 and does not show cross-reactivity 
with recombinant human MMP-2. Diluted serum sample (1:20 in assay 
buffer) was incubated overnight at 4°C on a tube rotator with 4 µg/ml of 
anti-MMP-9 antibody and 1 µl of 2.5% Triton. After this first step, 
Protein G Sepharose fast flow was added to the sample in a ratio of 1:3 
and incubated for 3 hours at 4°C on a tube rotator. After centrifugation, 
supernatant was removed and immunoprecipitation was repeated with the 
same antibody. The sample was then treated with Protein G Sepharose 
fast flow, as previously indicated, and finally centrifuged to obtain 
supernatant. The untreated serum and supernatant obtained after the two-
step immunoprecipitation were then tested for MMP-9 activities. 
 
Gelatinases separation by Concanavalin-A chromatography 
Serum MMP-2 and MMP-9 were separated by using a concanavalin-A-
Sepharose affinity chromatography following the method described 
earlier by Rantala-Ryhanen (Rantala-Ryhanen S et al., 1983) and adapted 
by us. Briefly, a microcolumn with 500 µl of concanavalin-A-Sepharose 
was equilibrated with PBS. After serum sample application the column 
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was washed with a 0.3 M NaCl buffer and then with a 0.3 M NaCl and 
50 mM methyl α-D-mannopyranoside buffer. Fractions of the flow 
through and wash were kept. Finally, the column was eluted with a buffer 
containing 0.5 M methyl α-D-mannopyranoside. The fractions were 
analyzed with gelatin zymography, MMP-2 and MMP-9 activity assays 
and MMP-9 inhibition by TIMP-1. 
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MMP-9 released from neutrophils  
 
Separation of Neutrophils from leukocytes-enriched Buffy Coats 
 
Used solutions: 
 Ficoll-Paque Plus (GE Healthcare); 
 Dextran 6% (dissolved in PBS); 
 Sodium Citrate (170 mM) / Citric Acid (76 mM) (anticoagulant); 
 Lysis Buffer: 30 mM NaCl, 10 mM NaH2PO4, pH 7.4; 
 Restoring Buffer: 270 mM NaCl, 10 mM NaH2PO4, pH 7.4. 
 
Neutrophils were isolated from buffy coats of healthy donors obtained 
from the blood bank, using density gradient centrifugation with Ficoll-
Paque PLUS (GE Healthcare) and sedimentation with dextran. The 
procedure was performed under a laminar flow hood to avoid any 
contamination. 
Briefly, the buffy coat was layered on the Ficoll in a sterile tube (buffy 
coat : Ficoll ratio 2:1). Then, the tubes were centrifuged at 2200 rpm for 
15 minutes at room temperature. 
After centrifugation, the supernatant (containing Ficoll, the PBMCs and 
PBS) was discarded from each tube and the remaining pellets, containing 
erythrocytes and granulocytes, were collected in a sterile tube adding 
anticoagulant and 6% dextran. The formed layers were mixed gently by 
inversion then left to settle at room temperature one hour in a vertical 
position. 
At the end of the incubation time, the upper layer containing the 
granulocytes was collected and centrifuged at 1100 rpm for 10 minutes.  
After centrifugation the supernatant was removed and the contaminating 
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RBCs were eliminated by hypo-osmotic lysis with Lysis Buffer, then, to 
restore the ionic strength Restoring Buffer was added. If necessary, the 
lysis procedure was repeated until neutrophils were no longer 
contaminated by RBCs. 
Finally, the cells were resuspended in 1 ml of 155 mM NaCl not buffered 
and 10 µl of the suspension were collected for the cell count. 
 
Stimulation of neutrophils with LPS 
4x106 cells were resuspended in 1 ml of RPMI 1640 medium previously 
adjusted to the necessary pH (6.6, 7.0, 7.4, 7.8, 8.2) and subjected to 
stimulation with 10 g/ml of LPS for 30 minutes at 37 °C. At the end of 
stimulation, the samples were centrifuged 10 minutes at 1100 rpm and 
the conditioned media were collected and then stored at -80 °C until 
MMP-9 assay. 
 
Stimulation of neutrophils with IL-8 
4x106 cells were resuspended in 1 ml of RPMI 1640 medium previously 
adjusted to the necessary pH (6.6, 7.0, 7.4, 7.8, 8.2) and subjected to 
stimulation with 20 ng/ml of IL-8 for 30 minutes at 37 °C. At the end of 
stimulation, the samples were centrifuged 10 minutes at 1100 rpm and 
the conditioned media were collected and then stored at -80 °C until 
MMP-9 assay. 
 
Total MMP-9 Assay (ELISA) 
The concentration of total MMP-9 in culture media was determined using 
a commercial kit from GE HealthCare (RPN 2614); all reagents useful 
for the determination (wells coated with specific antibodies, standard, 
buffers and detection reagent) were included in the kit. 
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Briefly, 100 μl/well of diluted medium were placed in a 96 well 
microtiter plate, together with a serial dilution (in duplicate) of MMP-9 
standard in a range 1-16 ng/ml and using dilution buffer as blank. After 1 
hour of incubation at room temperature and four wash cycles, the MMP-
9 present in the sample was bound to the wells of the plate. 
Afterwards, 100 μl of anti-MMP-9 HRP-conjugated antibody were 
dispensed in all wells and the plate was incubated for 2 hours at room 
temperature. At the end of incubation, four wash cycles were performed 
with wash buffer to remove the excess of secondary antibody. Then, 100 
μl of detection reagent (ready to use TMB/H2O2 mix) were dispensed in 
all wells and the plate was incubated 20 minutes at room temperature 
with slow shaking. 
The reaction was stopped with 100 μl of 1M H2SO4 and the absorbance 
read with a microplate reader at a wavelength of 450 nm. The amount of 
MMP-9 present in each sample was determined by interpolation with the 
standard curve. 
 
Statistics 
Comparisons of pHs with the control group 7.4 were performed by One 
Way ANOVA using the Dunnett’s post-hoc test. The comparisons 
between the acid and basic pHs were performed by One Way ANOVA, 
using the Bonferroni post-hoc test excluding the control group 7.4. 
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Neurofilament subunits and NAA in progressive multiple 
sclerosis 
 
Patients and controls 
We included PP (n = 28, according to Lublin and Reingold) (Lublin and 
Reingold, 1996) and transitional progressive (n = 10, according to 
Thompson et al.) (Thompson AJ et al., 1997) MS patients. Transitional 
progressive MS are patients with a progressive course without relapses, 
which are characterized by a single relapse before or after the onset of 
disease progression (Stevenson et al., 1999). Because of their similarities, 
PPMS and TPMS patients were considered as a unique patient group, 
defined as progressive hereafter. Of these, a subgroup of 21 patients 
participated in a phase II randomized, double-blind, placebo-controlled 
trial of interferon-beta (IFNβ)-1b (Montalban et al., 2009), where 10 
patients (8 PPMS, 3 transitional progressive patients) were treated with 
subcutaneous IFNβ-1b and 11 patients (7 PPMS, 3 transitional 
progressive patients) received placebo. As for patients who were not part 
of the clinical trial, 16 patients were untreated and 1 patient was 
receiving treatment with azathioprine at the time of CSF evaluation. The 
local ethical committee approved the study and informed consent was 
obtained from all participants. 
The control group was composed of patients with non-inflammatory 
neurological diseases (OND, n = 15): headache (n = 7), vertigo (n = 3), 
hydrocephalus secondary to tumor (n = 1), trigeminal neuropathy (n = 1), 
polyradiculopathy (n = 1), vestibular syndrome (n = 1), epilepsy (n = 1). 
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Preparation of cell-free CSF 
CSF samples were collected by lumbar puncture and centrifuged for 5 
min at 1500 rpm to remove cells. The cell-fee CSF supernatants were 
aliquoted and stored at –80ºC. In patients that participated in the clinical 
trial, the median time (interquartile range) between the study onset and 
CSF collection was 11.8 months (11.6–14.9 months), and was similar 
between placebo and IFNβ treated patients [12.0 months (11.7–14.7 
months) vs. 11.8 months (11.6–15.0 months) respectively]. 
 
CSF NAA measurements 
NAA was measured using a modified stable isotope dilution gas 
chromatography-mass spectrometry method, as previously reported 
(Jakobs et al., 1991; Teunissen et al., 2009). The intra-assay and inter-
assay CV were 2% (n = 8) and 2% (n = 6). All samples were analyzed 
within the linear range of the standard curve (0-0.5 nmol). 
 
CSF Neurofilament measurements 
Nf light ELISA 
Nf light was determined essentially as described before (Norgren et al., 
2004), however the first antibody was replaced by the in-house produced 
anti-Nf light monoclonal antibody, clone 4F8. For Nf light the inter-assay 
CV was 27.5% and intra-assay CV was 9.5%. 
 
Nf heavy Luminex assay 
Nf heavy was measured in a novel home-made developed multiplex 
assay. Activated beads from Qiagen (USA) were covalently immobilized 
with an anti-Nf heavy monoclonal antibody (9C9 generously provided by 
Carsten Korth, Germany). After blocking the Durapore filter plates 
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(HTS screening plates, Millipore) with PBS/2%BSA/0.05% Tween-20; 
50 L of standard (Nf heavy, Cat. 62010, Progen), controls, CSF 
samples, and blanks were incubated with a suspension of coupled beads 
(2500 beads/well) for 14-18 hours at 4C on an orbital plate shaker (600 
rpm). CSF samples were 5 times diluted in PBS/1% BSA/ 6 mM EDTA. 
After washing with PBS/1%BSA/0.05% Tween-20, the wells were 
incubated with 25 L of a 1:1000 diluted detector antibody (PAb--Nf 
heavy, Cat. N4142, Sigma, The Netherlands) for 1 hour at room 
temperature under continuously shaking (600 rpm). After washing, wells 
were incubated with 50 L of a 1:200 diluted phycoerythrin labelled 
donkey-anti-rabbit-polyclonal antibody (Cat. 711-116-152, Jackson 
ImmunoResearch) for 1 hour at room temperature under continuously 
shaking (600 rpm). The plate was then washed again and 100 L reading 
solution (Bio-plex Sheath fluid) was applied. The plate was read on a 
Bio-Plex 200 System (Bio-Rad) (50-100 beads/well). The mean 
fluorescence intensity data were analyzed using a 5-parameter logistic 
curve-fitting method and sample concentrations were calculated. All 
analyses were performed in duplicate and normalized to quality controls. 
Inter-assay CV was 18.4% and intra-assay CV was 5.4%. 
 
Statistics 
Normality of distributions was tested with the Shapiro-Wilk test. Since 
normality could not be assumed for the majority of variables, CSF data 
for axonal damage are represented as medians and multiple comparison 
were performed using a Kruskal-Wallis test. Two-group comparisons 
were performed using a Mann-Whitney U test. Possible relationships 
among all the variables and clinical data were assessed using the 
Spearman’s rank correlation coefficient test. Frequency distributions 
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were examined using the Fisher’s exact test. To control for possible 
confounding factors, such as age or therapy usage, analysis of variance 
was performed on the ranks of the biomarker levels. For all the tests, a 
P<0.05 was considered significant. 
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RESULTS 
 
Active MMP-2 and TIMP-2 in Multiple Sclerosis Patients 
 
Cerebrospinal fluid and serum levels and intrathecal synthesis of 
active MMP-2 and TIMP-2 in MS patients and controls 
Cerebrospinal fluid and serum concentrations of active MMP-2 and 
TIMP-2 were detectable in 100% of cases in RRMS, OIND, and NIND. 
As reported in the table 5, CSF and serum mean levels of active MMP-2 
were statistically different among the groups of patients examined 
(p<0.001 and p<0.02, respectively). Specifically, CSF and serum mean 
concentrations of active MMP-2 were significantly higher in RRMS 
(p<0.001 and p<0.05, respectively) and in OIND (p<0.01 and p<0.05, 
respectively) than in NIND. On the other hand, while CSF mean values 
of TIMP-2 were statistically different among the groups evaluated 
(p<0.01), serum mean levels of TIMP-2 did not statistically differ among 
RRMS, OIND, and NIND. In particular, CSF mean concentrations of 
TIMP-2 were significantly more increased in OIND (p<0.01) than in 
RRMS and in NIND, without statistical differences for these values 
between RRMS and NIND. In addition, CSF mean values of active 
MMP-2/TIMP-2 ratio were statistically different among the groups 
analysed (p<0.01), whereas only a trend toward a statistically difference 
(P = 0.0602) was found for serum mean values of active MMP-2/TIMP-2 
ratio among RRMS, OIND, and NIND. More precisely, CSF and serum 
mean values of active MMP-2/TIMP-2 ratio were significantly greater in 
RRMS than in NIND (p<0.001 and p<0.05, respectively), without any 
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Cerebrospinal fluid and serum levels and intrathecal synthesis of 
active MMP-2 and TIMP-2 in MS patients categorized according to 
clinical and MRI activity 
When MS patients were grouped according to clinical activity, there were 
no statistical differences between RRMS patients with and without 
clinical evidence of disease activity for CSF and serum mean 
concentrations of active MMP-2 and TIMP-2, for CSF and serum mean 
values of active MMP-2/TIMP-2 ratio, and for intrathecal production of 
active MMP-2 and TIMP-2 (data not shown). On the other hand, when 
MS patients were stratified according to MRI activity, CSF mean levels 
of active MMP-2 significantly increased more (p<0.02) in RRMS 
patients with MRI inactive (4.0 ± 4.6 ng/mL) than in those with MRI 
active disease (1.9 ±1.7 ng/mL) (figure 26, panel A), whereas serum 
mean concentrations of TIMP-2 were significantly more pronounced 
(p<0.0001) in MRI active (63.7 ± 49.2 ng/mL) than in MRI stable (29.3 ± 
16.7 ng/mL) RRMS patients (figure 26, panel B). Furthermore, CSF and 
serum mean values of active MMP-2/TIMP-2 ratio were significantly 
higher (p<0.01) in RRMS patients with MRI stable (8.2 ± 14.4 × 10−2 
ng/mL and 18 ± 25.7 ng/mL, respectively) than in those with MRI active 
disease (4.1 ± 8.2 × 10−2 ng/mL and 10 ± 19.2 ng/mL, respectively) 
(figure 26, panel C and D). Next, an intrathecal synthesis of active 
MMP-2 was significantly more frequent (p<0.001) in RRMS patients 
without MRI appearance of disease activity (58.8%) than in those with 
disease activity as measured by MRI scans (18.2%) (figure 26, panel E). 
We did not observe other significant differences between RRMS patients 
with and without Gd- enhancing lesions for serum active MMP-2 mean 
levels, for CSF TIMP-2 mean concentrations, and for intrathecal 
synthesis of TIMP-2 (data not shown). 
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Active gelatinases and TIMPs in SICH  
 
MMPs and TIMPs time course 
As illustrated in figure 28, serum mean levels of active MMP-9 and 
MMP-2 were statistically different over time (p<0.0001). Specifically, in 
comparison to baseline mean values observed at 24 hours (6.1 ± 3.7 
ng/ml), serum active MMP-9 mean concentrations (panel A) were 
significantly higher at 48 hours (7.5 ± 4.0 ng/ml; p<0.05) and at 7 days 
(9.5 ± 4.1 ng/ml; p<0.0001). In addition, serum active MMP-9 mean 
levels were significantly more elevated at 7 days than at 48 hours 
(p<0.02). On the other hand, serum mean titers of active MMP-2 (panel 
B) were significantly lower at 48 hours (154.5 ± 110.9 ng/ml; p<0.01) 
and at 7 days (117.8 ± 93.7 ng/ml; p<0.0001) than at baseline (194.1 ± 
122.7 ng/ml). Moreover, serum active MMP-2 mean levels were 
significantly decreased at 7 days as compared to 48 hours (p<0.01). No 
statistical differences were found among the time points examined for 
serum mean levels of TIMP-1 and TIMP-2 (data not shown). 
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temporal profile of serum MMP-9, MMP-2, TIMP-1 and TIMP-2 mean 
levels and hematoma and perihematomal edema volumes (data not 
shown). Serum MMPs and TIMPs measurements were not significantly 
correlated to NIHSS in the different time points analysed. 
 
Table 6. Significant correlations between serum mean levels of MMP-9 and MMP-2 
and hematoma and perihematomal edema volumes in 28 patients with spontaneous 
intracerebral hemorrhage (SICH). 
Spearman’s correlation Correlation 
coefficient 
Significance 
MMP-9 vs. hematoma volume  
at 24 hours from onset 
r = 0.394 p < 0.05 
MMP-9 vs. hematoma volume 
at 48 hours from onset 
r = 0.447 p < 0.02 
MMP-2 vs. hematoma volume 
at 7 days from onset 
r = - 0.405 p < 0.05 
MMP-9 vs. edema volume 
at 24 hours from onset  
r = 0.460 p < 0.02 
MMP-9 vs. edema volume  
at 48 hours from onset 
r = 0.422 p < 0.05 
MMP-2 vs. edema volume  
at  24 hours from onset 
r = 0.385 p < 0.05 
MMP-2 vs. edema volume  
at 7 days from onset 
r = - 0.471 p < 0.02 
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Detection of 66 kDa active MMP-9 in Serum 
 
Inhibition of MMP-9 by TIMP-1 
To verify whether inhibition by TIMP-1 is useful to distinguish between 
the 82 kDa and 66 kDa active forms of MMP-9, we performed a time-
dependent activation of MMP-9. As shown in figure 30 (panel A) an 
increasing incubation time with APMA corresponded to a decreasing 
intensity of the gelatinolytic bands at high molecular weights (pro-MMP-
9 and 82 kDa MMP- 9, respectively) and an associated increasing 
intensity of the lower molecular weight band (66 kDa MMP-9). It must 
be noted that there was a band between 82 kDa and 66 kDa forms, most 
likely representing an intermediate form in the process of activation 
(Okada Y et al., 1992). These findings confirmed that in the presence of 
APMA, pro-MMP-9 was converted into the 82 kDa form and then into 
the 66 kDa form. 
The same samples were assayed also for the MMP-9 activities. As 
indicated in figure 30 (panel B), the total MMP-9 activity (circles) 
increased with the incubation time, due to the progressive conversion of 
the inactive 92 kDa form to the active 82 kDa and 66 kDa forms. When 
TIMP-1 was added to the assay mixture the uninhibited activity (figure 
30, panel B, filled squares), which was very low at time zero, showed a 
remarkable time-dependent increase indicating that under the assay 
conditions only a part of the active enzyme was inhibited. Furthermore, 
the uninhibited activity increased in parallel with the 66 kDa band 
intensity, showing a strong positive correlation with the zymographic 
data (figure 30, panel C) (p<0.01; Pearson correlation r = 0.9987). This 
suggested that the assay performed in presence of TIMP-1 allowed a 
quantitative evaluation of the 66 kDa form. 
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MMP-9 released from neutrophils 
 
Levels of MMP-9 released by not stimulated neutrophils 
Table 7 shows the mean MMP-9 levels in absence of stimuli, at different 
pHs. 
Comparing the levels of MMP-9 released at different pH with the control 
group 7.4 (physiological pH) we found significant higher levels of MMP-
9 at more acidic pH (6.6) (figure 34; One way ANOVA, Dunnet’s post-
hoc test vs. 7.4; p<0.01). Moreover, the levels of MMP-9 were higher 
than all the other pHs (table 10), whereas comparable levels were found 
between pH 7.0, 7.8 and 8.2. 
  
Table 7. Levels of total MMP-9 (ng/ml) released at different pH by not stimulated 
neutrophils. 
Values are represented as mean  SD of 5 experiments. To compare the levels of MMP-
9 a one way ANOVA followed by a Dunnett’s post-hoc test using pH 7.4 as control was 
performed. ns = not significant (p>0.05). 
pH MMP-9 released (ng/ml) 
mean  SD 
Significance 
(pH vs. 7.4) 
6.6 978,00  5,51 p<0.01 
7.0 810,48  32,63 ns 
7.4 780,89  73,08 - 
7.8 668,73  54,35 ns 
8.2 717,33  48,94 ns 
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Table 8. Levels of total MMP-9 (ng/ml) released by neutrophils stimulated with LPS. 
Values are represented as mean  SD of 5 experiments. To compare the levels of MMP-
9 a one way ANOVA followed by a Dunnett’s post-hoc test using pH 7.4 as control was 
performed. ns = not significant (p>0.05). 
pH MMP-9 released (ng/ml) 
mean  SD 
Significance 
(pH vs. 7.4) 
6.6 1358.67  70.43 p<0.05 
7.0 1403.09  103.73 p<0.01 
7.4 1187.33  13.26 - 
7.8 1081.40  10.46 ns 
8.2 947.27  60.83 p<0.01 
 
Figure 35 shows the curse of MMP-9 levels measured at different pHs. 
We observed a pH-dependent release of MMP-9 when neutrophils were 
stimulated with LPS: there was an increase at low pH values (6.6 and 
7.0) and a decrease at higher pH (8.2), respect the 7.4 (table 8). 
However, the amount of MMP-9 released at pH 7.8 and 7.4 did not 
differ. 
Moreover, significant higher levels of MMP-9 released at acid pHs than 
the basic pHs were found (table 10), whereas no differences were 
observed between the two acid pH (6.6 vs.7.0), or the two basic pH (7.8 
vs. 8.2) (table 10).  
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physiological pH (7.4), with significant lower levels at more acid pH 
(6.6) and both basic pHs (7.8 and 8.2) (table 9). 
 
Table 10. One way ANOVA followed by Bonferroni post-hoc test. 
The comparison with the control group 7.4 were excluded. ns = not significant 
(p>0.05). 
Comparison Significance 
 not stimulated LPS IL-8 
6.6 vs 7.0 p<0.05 ns p<0.01 
6.6 vs 7.8 p<0.001 p<0.01 ns 
6.6 vs 8.2 p<0.001 p<0.001 ns 
7.0 vs 7.8 ns p<0.001 ns 
7.0 vs 8.2 ns p<0.001 p<0.01 
7.8 vs 8.2 ns ns ns 
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Neurofilament subunits and NAA in progressive multiple 
sclerosis 
 
CSF NAA, Nf light and Nf heavy levels in patients with progressive 
MS and controls with OND 
The levels of NAA, Nf light and Nf heavy were detectable in 100% of 
MS patients and OND (table 11). We first compared CSF levels of NAA, 
Nf light and Nf heavy between the whole MS group and controls with 
OND. As shown in figure 37 (panel A and B), NAA and Nf light levels 
were comparable between the two groups. However, Nf heavy levels 
were two fold higher in MS patients than OND controls (P<0.001; 
Figure 37, panel C). Of note, NAA, Nf light and Nf heavy levels were 
comparable between transitional progressive (n = 10) and primary 
progressive (n = 28) MS patients (P = 0.260, data not shown). 
Since part of the patients in the progressive MS group were receiving 
treatment with IFNβ-1b as part of the clinical trial, we evaluated whether 
IFNβ-1b could affect CSF Nf light, Nf heavy and NAA levels by 
stratifying patients into treated (n=10) and untreated (n=11) groups. 
While NAA and Nf light were very similar between the two groups 
(P<0.05; data not shown), we found only a trend towards a statistical 
significant difference in the Nf heavy levels (figure 37, panel D; P = 
0.067). Of note, CSF Nf heavy levels remained significantly higher in 
untreated MS patients compared to controls after correction for IFNβ-1b 
usage (P=0.004; data not shown). No effect of age was observed (data 
not shown). 
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Combination of CSF biomarkers for axonal damage improves 
discrimination between MS patients and controls 
Based on the 90% cut-off values of the levels of Nf light, Nf heavy and 
NAA in the OND group (figure 37 A-D, dashed horizontal line), we 
defined in all subjects whether Nf light or Nf heavy were increased and 
whether the NAA levels were increased or decreased. None of the 
patients had simultaneous increased Nfs and increased or decreased 
NAA, but 7 patients out of 38 (18.1 %) and 1 control out of 15 (6.7 %) 
showed simultaneous increase in both Nfs.  
Abnormal axonal damage biomarkers were more frequent in progressive 
MS patients than controls (Fisher Exact test, 55% vs. 20%, P<0.05) and 
the combination of biomarkers allowed us to classify a higher number of 
patients with abnormal biomarker levels than single markers (table 12). 
No difference was found in the EDSS scores in patients with abnormal 
and normal axonal damage biomarkers, indicating that the combination 
of the three biomarker levels seemed not related to worse clinical 
condition within the progressive MS group, although Nf heavy only was, 
as shown before.  
In addition, we determined the cut-off values for the biomarkers based on 
the first and third tertile in the whole OND and MS merged group and we 
analysed if high levels of Nf light, Nf heavy and low or high values of 
NAA could be predictive for progressive MS. 
We found that Nf levels in the upper tertile were related to a Odds ratio 
of 7.2 to be in the group of the progressive MS patients (ODDS ratio 7.2; 
95 % Confidence Interval 1.3 - 38.2;  P<0.025). Indeed, Nf light or NAA 
did not improve the model. 
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Table 12. Percentage of progressive MS patients and OND controls with abnormal 
biomarker values. 
The percentages are defined by single markers or the combination of Nfs and NAA. 
Percentage abnormal in each subgroup 
 Progressive MS OND 
NAA ↓ 21.1 % (8/38) 6.7 % (1/15) 
Nfs (Nf light ↑ AND Nf heavy ↑) 18.4 % (7/38) 6.7 % (1/15) 
Nfs (Nf light ↑ OR Nf heavy ↑) 42.1 % (16/38) 13.3 % (2/15) 
NAA or Nfs 55.3 % (21/38) 20 % (3/15) 
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DISCUSSION 
A biomarker is defined as a quality objectively measured and evaluated 
as indicator of physiological and pathological processes or 
pharmacologic responses to a therapy (Biomarkers Definitions Working 
Group, 2001). Often, to monitor a disease only one biomarker that has 
proven to be specific for that pathology is used. The results found in the 
present study improve the concept of the use of different biomarkers 
related to pathologies. In fact, not only a single biomarker could be 
useful to monitor a disease, but especially the combination of biomarkers 
can give a more accurate sight of a disease state. A clear example is the 
combination of different biomarkers of axonal damage, such as 
Neurofilaments (Nf) light and heavy and N-acetylaspartic acid (NAA), 
which recently has been hypothesized as a good choice to monitor the 
different stages of axonal degeneration in Multiple Sclerosis (MS) 
(Teunissen CE et al., 2009). In particular, it has been shown that Nf light 
levels may be a biomarker for acute axonal damage caused by 
inflammation. On the other hand, the levels of Nf heavy may increase 
during irreversible late-stage axonal degeneration, whereas NAA 
probably increase during early stages of acute axonal damage, being 
increasingly excreted as a consequence of increased mitochondrial 
activity. However, decreased NAA levels likely reflect the axonal loss at 
the end stage of the process of axonal degeneration (Teunissen CE et al., 
2009). The results we found in our study about biomarker levels in a 
relatively large cohort of essentially progressive MS patients, 
characterized by prominent axonal degeneration rather than inflammation 
(Kutzelnigg A et al., 2005), are in line with these assumptions. In fact, 
we did not find any difference on the Nf light levels between patients 
with a progressive course of disease (PPMS) and controls with other 
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neurological diseases (OND). This suggests that Nf light may be 
associated to relapse-onset or inflammation-induced axonal loss or 
injury, since it is increased during relapses and normalized during 
remission phases (Norgren N et al., 2004). Also, we can hypothesize that 
lower NAA levels may reflect the black hole formation, as we found a 
negative correlation between its levels and the lesion burden measured by 
T1 weighted Magnetic Resonance Imaging (MRI). However, the median 
NAA levels in progressive MS patients were similar to controls, arguing 
the possibility that NAA lowering is a common process which may be 
not-specific for MS. Furthermore, we can confirm that Nf heavy is 
associated to irreversible axonal damage, since we found significant high 
levels of this marker in PPMS patients. Therefore, our results suggest that 
Nf heavy can be considered as a surrogate marker of axonal damage in 
patients with essentially progressive MS course. Finally, using the 
combination of the biomarkers we were able to classify a higher number 
of patients with MS with abnormal axonal damage biomarker values than 
for single markers. This confirms that together these biomarkers may 
reflect different stages of axonal damage  (Teunissen CE et al., 2009) and 
this can give a more accurate sight of the disease. 
Different pathological processes can take place during MS: beside the 
axonal damage, which accumulates during the course of the disease and 
is responsible for the major disability experienced by patients, also 
inflammation has a key role (Hauser S et al., 2006). In fact, the triggered 
inflammatory response can lead to the recruitment of cells from the 
immune system which can in turn cause tissue damage as well as axonal 
degeneration (Martino GV et al., 2002; Hauser S et al., 2006). For this 
reason, we also studied the possible role of the gelatinases in pathologies 
with a neuroinflammatory component. The ability of MMP-9 and MMP-
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2, the two gelatinases, to degrade components of the extracellular matrix 
and to regulate the activity of a number of soluble proteins confers an 
important role to various physiological and pathological processes (Van 
den Steen PE et al., 2002). A growing body of evidence has accumulated 
associating MMP-9 to inflammatory conditions, in particular to 
neuroinflammation (Rosenberg GA, 2002; Van den Steen PE et al., 2002; 
Tejima E et al., 2007). Indeed, MMP-9 can impair the Blood Brain 
Barrier (BBB), favoring the recruitment of inflammatory cells into the 
Central Nervous System (CNS) increasing the ongoing inflammation 
(Opdenakker G et al., 2003). Conversely, the significance of MMP-2 in 
inflammation seems controversial: in fact, especially in 
neuroinflammation MMP-2 has been associated to both protective and 
harmful role (Rosenberg GA, 2002; Yong VW, 2005; Yong VW et al., 
2007). However, its real role is still unclear. 
Previously, we identified in the active MMP-9 and the active MMP-
9/TIMP-1 ratio good surrogate biomarkers for disease progression and 
activity in Relapsing-Remitting Multiple Sclerosis (MS) (Fainardi E et 
al., 2006). In particular, in such neuroinflammatory disease we found 
both increased active MMP-9 and MMP-9/TIMP-1 ratio in patients 
during active stage of disease than in those inactive. Moreover, the levels 
of MMP-9 were higher in patients with MS and other inflammatory 
neurological diseases (OIND) than the one with non-inflammatory 
neurological disease (NIND), confirming that MMP-9 is implicated in 
neuroinflammation (Fainardi E et al., 2006). The results we found in the 
present study about patients affected by SICH (Spontaneous Intracerebral 
Hemorrhage), another disease with a major inflammatory component, 
confirm the key role of MMP-9 in neuroinflammation. In fact, active 
MMP-9 levels rose over time moving from the acute to the subacute 
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phase compared to baseline levels. Also, a gradual increase in 
perihematomal edema volume was seen over time. More interestingly, 
MMP-9 levels were positive correlated with the perihematomal edema 
suggesting that MMP-9 is strictly related to neuroinflammation, as the 
edema formation is associated to a triggered inflammatory response. 
Thus, MMP-9 may exert a detrimental effect impairing the BBB and 
exacerbating the perihematomal edema formation (Abilleira S et al., 
2003). On the contrary, our findings about active MMP-2 support the 
hypothesis of a protective function of this enzyme, favoring the 
resolution of neuroinflammation and tissue repair. In fact, we found a 
decrease in active MMP-2 levels over time in SICH patients and a 
negative correlation with perihematomal edema, suggesting an opposite 
role of MMP-2 than MMP-9 in neuroinflammation. Moreover, the results 
found in our study about MS support the repairing role of MMP-2. 
Higher active MMP-2 levels we found here in MS patients and in OIND 
than NIND, confirm that MMP-2 is implicated in the regulation of 
neuroinflammation (Yong VW, 2005). More attractive were the results 
coming from the analysis of MS patients that revealed the presence of 
more increased concentrations of active MMP-2 during Magnetic 
Resonance Imaging (MRI) inactive than MRI active stage of disease. 
Moreover, TIMP-2 levels were greater in MS patients with than in those 
without MRI evidence of disease activity. As MRI Gd-enhancement is 
widely accepted to be more powerful than clinical examination in 
measuring MS disease activity (Miller DH et al., 1993), this implies that 
a shift in MMP-2/TIMP-2 balance toward activity of MMP-2 could be 
involved in mechanisms leading to the resolution of neuroinflammation, 
which are associated with the remission of the disease. Therefore, our 
findings argue for a potential role of CSF and serum levels of active 
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MMP-2 as appropriate indicators of the termination of MS inflammatory 
disease activity. In particular, serum active MMP-2/TIMP-2 ratio may be 
useful as a surrogate biomarker for monitoring MS disease recovery 
since it is easily measurable. 
Therefore, our results suggest a possible different implication of the two 
gelatinases in ongoing inflammatory response taking place in the CNS: 
MMP-9 may promote the disruption of the BBB increasing the 
inflammation, whereas MMP-2 might exert a protective function 
favouring the resolution of neuroinflammation. Thus, the combination of 
the active MMP-9 and MMP-2 might be useful to monitor the different 
stages of an inflammatory disease. 
In addition, the involvement of MMP-9 in inflammation has been shown 
by in vitro experiments where we studied the release of MMP-9 from 
neutrophils subjected to environmental pH changes. In fact, it is well 
documented that an acidic pH is present in inflamed tissues and that this 
environmental condition can influence the immune response (Kellum JA 
et al., 2004; Trevani AS et al., 1999; Martinez D et al., 2006). Thus, the 
finding of more MMP-9 released during extracellular acidosis suggests 
that neutrophils can be activated by this condition, increasing their 
response. Therefore, a more prominent production of MMP-9 can be 
directly associated to inflammation. In addition, supporting this 
hypothesis we found that extracellular pH can also modulate the response 
of these cells to pro-inflammatory stimuli. In fact, we found a different 
behavior on the basis of the used stimulus: when neutrophils were 
subjected to LPS stimulation, there was an increase of MMP-9 release at 
acid pH, whereas when stimulated with IL-8 a decrease occurred, 
compared to physiological pH (7.4). A possible explanation of this not-
conventional behavior could be the different role of the used stimuli. In 
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fact, while IL-8 is used to recruit neutrophils towards the site of 
inflammation from an environment with a physiological pH, LPS have to 
trigger a strong consistent response against pathogens. Conversely, a 
basic environment seems to affect negatively the release of MMP-9 with 
both stimuli, according to previous observation on diminished 
neutrophils functions during extracellular alkalosis (Kleinberg I. et al., 
1968). Our observations are in line with studies that report a positive 
modulation of neutrophils functions by extracellular acidosis (Trevani 
AS et al., 1999; Martinez D et al., 2006), whereas are contrasting with 
other studies that report a negative modulation (Lardner A. et al., 2001; 
Murata N et al., 2009). 
Finally, the finding of the 66 kDa active MMP-9 in serum of healthy 
subjects opens new avenues in understanding the implication of MMP-9 
in inflammation and its role as marker. In fact, our results suggest that 
this particular form is normally present in serum in variable amounts in 
relation to total endogenous active MMP-9 concentration. This may 
indicate that the 66 kDa MMP-9 is not likely a background artifact due to 
autoproteolysis of the sample, as thought up to now (O’Connell JP et al., 
1994). Therefore, this form of MMP-9 deserve more attention as it might 
not be inhibited by TIMP-1: the unbalance of the activation network 
towards a more prominent production of the 66 kDa form can lead to 
both increased tissue damage and inflammation. However, the main 
limitation of our study is the inability to establish the actual functional 
properties of this active MMP-9. In fact, it is not clear yet whether the 
balance between 82 kDa and 66 kDa MMP-9 has a physiological 
significance, although we can hypothesize that this might reflect the 
activity of the enzymes upstream the activation cascade of MMP-9. 
However, further studies including several inflammatory pathologies as 
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well as a large cohort of healthy subjects are necessary. Collectively 
taken, our results evidence the key role that MMP-9 might has in 
inflammation, since it can act both directly and indirectly increasing 
tissue damage and reinforcing the inflammation itself (Van den Steen PE 
et al., 2002). 
 
From our study, we can conclude that the presence of more biomarkers 
which reflect different aspects of pathological processes and their 
combination can have a predicting value for the evolution of a disease, 
also giving useful information in therapies efficiency. 
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